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Small molecule compounds targeting DNA binding domain of STAT3 
for inhibition of tumor growth and metastasis 
 
Signal transducer and activator of transcription 3 (STAT3) is constitutively 
activated in malignant tumors, and its activation is associated with high histological 
grade and advanced cancer stage. STAT3 has been shown to play important roles 
in multiple aspects of cancer aggressiveness including proliferation, survival, self-
renewal, migration, invasion, angiogenesis and immune response by regulating 
the expression of diverse downstream target genes. Thus, inhibiting STAT3 
promises to be an attractive strategy for treatment of advanced tumors with 
metastatic potential. We firstly identified a STAT3 inhibitor, inS3-54, by targeting 
the DNA-binding site of STAT3 using an in-silico screening approach; however, 
inS3-54 was finally found not to be appropriate for further studies because of low 
specificity on STAT3 and poor absorption in mice. To develop an effective and 
specific STAT3 inhibitor, we identified 89 analogues for the structure-activity 
relationship analysis. By using hematopoietic progenitor cells isolated from wild-
type and STAT3 conditional knockout mice, further studies showed that three 
analogues (A18, A26 and A69) only inhibited STAT3-dependent colony formation 
of hematopoietic progenitor cells, indicating a higher selectivity for STAT3 than 
their parental compound, inS3-54. These compounds were found to (1) inhibit 
STAT3-specific DNA binding activity; (2) bind to STAT3 protein; (3) suppress 
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proliferation of cancer cells harboring aberrant STAT3 signaling; (4) inhibit 
migration and invasion of cancer cells and (5) inhibit STAT3-dependent expression 
of downstream targets by blocking the binding of STAT3 to the promoter regions 
of responsive genes in cells. In addition, A18 can reduce tumor growth in a mouse 
xenograft model of lung cancer with little effect on body weight. Taken together, 
we conclude that it is feasible to inhibit STAT3 by targeting its DNA-binding domain 
for discovery of anticancer therapeutics. 
 
Jian-Ting Zhang, Ph.D., Chair  
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I. Introduction 
A. Signal transducers and activators of transcription 
Signal transducers and activators of transcription (STATs) are a family of 
proteins which act as signal transducers and transcription activators in cells, 
including STAT1, STAT2, STAT3, STAT4, STAT5 and STAT6. STATs remain 
inactive in the cytoplasm under normal condition. Upon the binding of cytokines 
and growth factors to their receptors, STATs are phosphorylated by receptor-
associated kinases, form dimers and translocate to cell nucleus to activate 
transcription of specific responsive genes. The discovery of STATs begins with the 
studies of interferon (IFN)-mediated gene expression (1). STAT1 and STAT2 are 
the earliest recognized STAT proteins which are required for IFN-activated gene 
expression (2-5). STAT1 maintains cellular homeostasis through the control of cell 
growth, proliferation, apoptosis and immune reactions (6). STAT1-deficient mice 
spontaneously developed tumors and loss of its expression is frequently detected 
during cancer progression, suggesting its critical role as a tumor suppressor (7). 
STAT2 is involved in IFN-dependent cellular antiviral response and adaptive 
immunity, thereby medicating host defenses against viral infections (8, 9). STAT4, 
which was initially observed to respond to interleukin-12 (IL-12), is involved in 
regulating cell proliferation, differentiation and lymphocyte function, e.g. T helper 
1 cells and natural killer cells (10, 11). STAT5a and STAT5b are found to be two 
distinct duplicated genes which are distributed differently in a variety of tissues (12, 
13). Their structures are over 90% identical but only diverse at the C-terminus. 
STAT5 primarily plays a crucial role in cell development (14). The last identified 
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STAT protein is STAT6 which is mainly expressed in bone marrow-derived cells 
and regulates immune response and cell development (15). Overall, STAT protein 
family plays diverse roles in cellular functions such as cell proliferation, 
differentiation, metastasis, angiogenesis and immune response. 
 
B. STAT3 activation and protein structure 
As a well-known member of STAT protein family, STAT3 was initially 
observed to respond to IL-6 and epidermal growth factor (EGF) (16). Numerous 
scientists then contributed to uncovering the complete signaling pathway (1, 17-
20). As shown in Figure 1, the binding of IL-6 family cytokines to glycoprotein 130 
receptor activates the receptor-associated Janus kinase 2 (JAK2) which then 
phosphorylates specific tyrosine residues of the receptor, followed by recruitment 
of STAT3 to the receptor via its Src homology 2 (SH2) domain. Activated JAK2 
then triggers the phosphorylation of STAT3 at tyrosine 705 (Tyr705), leading to the 
dissociation of STAT3 from the receptor. Diverse growth factors were also 
observed to activate STAT3, such as EGF, hepatocyte growth factor (HGF) and 
platelet-derived growth factor (PDGF) (16, 21, 22). And STAT3 is also a target of 
non-receptor tyrosine kinases (23). Once activated, STAT3 protein forms dimers 
and translocates into cell nucleus where it binds to γ-interferon activation sequence 
(GAS) or interferon stimulated response element (ISRE) in the promoter regions 
of responsive genes, leading to activation of gene transcription. STAT3 target 
genes include regulators of crucial steps in cell proliferation, survival, differentiation 
and development, metastasis, angiogenesis and immune response (Table 1).  
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Figure 1. Schematic diagram of canonical JAK/STAT3 signaling pathway. 
Upon cytokines or growth factors binding to respective receptors, JAK is activated 
and phosphorylates the receptor which provides a docking site for STAT3. STAT3 
is then recruited to the receptor where it is phosphorylated and activated. 
Phosphorylated STAT3 dissociates from the cell surface and forms dimers for 
nucleus entry and transcription activation.   
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Table 1. Representative STAT3 downstream target genes 
Gene Function Reference* 
Cyclin D1 Cell cycle progression (24) 
C-myc Cell proliferation, cell growth, apoptosis, differentiation 
and stem cell self-renewal 
(25) 
Survivin Apoptosis suppressor (26) 
MMP-1 Breakdown of extracellular matrix (27, 28) 
MMP-2 Breakdown of extracellular matrix (29) 
MMP-7 Breakdown of extracellular matrix (30) 
MMP-9 Breakdown of extracellular matrix (31) 
MMP-10 Breakdown of extracellular matrix (32) 
Twist Cell lineage determination and differentiation (33) 
VEGF Vasculogenesis and angiogenesis (34, 35) 
* References represent the evidence showing the genes are transcriptionally 
regulated by STAT3.  
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The crystal structure of STAT3 protein bound to its DNA recognition site has 
been solved (36), providing insight into the function of STAT3. STAT3 consists of 
770 amino acids in five distinct functional domains (Figure 2). The amino-terminal 
domain (ND) is responsible for stabilizing the binding of STAT3 to multiple DNA 
sites (37). The coiled-coil domain (CCD) mediates protein-protein interaction (36). 
A linker connects the DNA-binding domain (DBD) and SH2 domain which are 
required for DNA binding and dimerization of STAT3, respectively (38, 39). The 
phosphorylated tyrosine is located at the residue Tyr705. Upon phosphorylation, 
two STAT3 monomers are coupled via their SH2 domains, forming a dimer to bind 
to DNA targeting sites with a 9-base-pair consensus sequence, TTCCGGGAA (36). 
DBD directly binds to the specific sequence in the promoters of STAT3 target 
genes. The carboxy-terminal transactivation domain (TAD) where the tyrosine 
residue is phosphorylated contacts other components of the transcriptional 
machinery to activate transcription of the target genes (40).  
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Figure 2. Schematic diagram of STAT3 structure. 
N-terminal domain is involved in cooperative DNA binding. Coiled-coil domain is 
important for interactions with other transcriptional regulation proteins. DNA-
binding domain directly contacts DNA. SH2 domain mediates formation of STAT3 
dimers. The C-terminal transactivation domain is responsible for the transcriptional 
activation of STAT3-regulated genes.  
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C. Regulation of STAT3 signaling and roles of aberrant STAT3 signaling in 
cancers 
As the activation of STAT3 is tightly regulated in cells under physiological 
condition, STAT3 signaling is latent and transiently activated in response to 
cytokines and growth factors. On the receptor level, direct ligand binding or 
receptor phosphorylation after ligand binding may trigger receptor endocytosis, 
thereby negatively regulating STAT3 signaling (41). Moreover, there are several 
negative regulators which act as protein tyrosine phosphatases (PTPs), e.g. Src 
homology region 2 domain-containing phosphatase-1 (SHP-1), SHP-2, 
phosphatase and tensin homolog (PTEN) and protein-tyrosine phosphatase  1D 
(PTP1D) (42-45). They may dephosphorylate receptors, kinases or STAT3, 
resulting in inactivation of STAT3 signaling. And protein inhibitors of activated 
STAT3 (PIAS3) can directly bind to STAT3, thereby preventing the binding of 
STAT3 to DNA and affecting the function of STAT3 (46). Additionally, activated 
STAT3 triggers transcription of diverse downstream target genes, including 
negative regulators which implicate in the termination of STAT3 signaling. STAT3 
transcriptionally activates suppressor of cytokine signaling proteins (SOCS), 
leading to a negative regulation of STAT3 signaling (47). SOCS proteins may bind 
to JAKs or the cytokine receptors, resulting in inhibition of JAK activity or 
competing with STATs for binding sites on the receptors. SOCS proteins can also 
cause receptor degradation through ubiquitin-proteasome-mediated process. 
In contrast to the strictly controlled normal cells, cancer cells usually harbor 
aberrant STAT3 signaling. Persistent activation of STAT3 may be derived from 
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constitutive activation of cytokine or growth factor receptors or aberrant activity of 
tyrosine kinases (48). Src oncoprotein also associates with enhanced activity of 
STAT3 (23, 49-51). As a result, aberrant gene transcription occurs in cancer cells 
and contributes to tumor cell survival and proliferation, tumor metastasis and 
angiogenesis as well as tumor immune evasion. As shown in Table 1, STAT3 
regulates expression of survivin which acts as an inhibitor of apoptosis (26). 
STAT3-dependent overexpression of survivin inhibits apoptosis, causing 
resistance to chemotherapy. STAT3 is also a transcription factor of c-Myc and 
cyclin D1, which are proliferation-promoting genes (24, 25). Additionally, STAT3 
involves in a variety of critical steps in metastasis and angiogenesis by regulating 
diverse genes (52-53). During tumor metastasis, individual tumor cells may break 
away from the original tumor and invade nearby vessels. Specifically, STAT3 
activation transcriptionally induces twist which regulates the essential process in 
metastasis initiation with loss of cell adhesion and improved cell mobility (33). 
STAT3 was also shown to regulate transcription of diverse matrix 
metalloproteinases (MMPs) which involve in degrading different proteins that make 
up the surrounding extracellular matrix and thus helping cancer cells separate from 
adjoining tissues, e.g. MMP-1, MMP-2, MMP-7, MMP-9 and MMP-10 (27-32). 
Once inside the blood vessels, some cancer cells may simply die. Some cells may 
be recognized and destroyed by immune cells. Other cells may survive and leave 
the blood vessels to a new location where they begin to reproduce, resulting in a 
secondary tumor formed when the tumor cells locate to a suitable 
microenvironment. However, solid tumor cannot grow beyond a limited size without 
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blood supply. STAT3 also contributes to tumor angiogenesis by transcriptional 
regulation of vascular endothelial growth factor (VEGF) which stimulates the 
growth of new blood vessels (34, 35). Furthermore, activated STAT3 has been 
also found to affect the interplay between tumor cells and host immune system 
(54). To sum up, activation of STAT3 is a tightly controlled transient process in 
normal cells under physiological condition whereas its aberrant signaling 
correlates to malignant transformation and tumorigenesis. 
 
D. Clinical implications of STAT3 
Cancer is a group of disease characterized by uncontrolled cell growth in 
humans. As a leading cause of mortality throughout the world, lung, stomach, liver, 
colon and breast cancers account for the most cancer deaths each year. In 
particular, deaths caused by lung cancer accounted for about 27% of all cancer 
deaths as of 2013 (55). And about 1 in 8 women in the United States will develop 
invasive breast cancer during their lifetime. Common cancer therapy includes 
surgery followed by chemotherapy and/or radiotherapy whereas the survival rates 
of cancer patients remain low due to late diagnosis or poor response to treatment. 
Prognosis and survival rates of cancers depend on various factors, such as cancer 
type, disease stage and treatment. By interfering with specific molecules that 
induce carcinogenesis and tumor growth, targeted therapy is expected to be more 
effective than the conventional chemotherapy which simply works on all rapidly 
dividing cells. Despite hormone-blocking therapy and HER2-targeted therapy are 
effective to treat hormone receptor-positive cancers by interfering with the effects 
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of hormones on breast cancers; however, same breast cancers, which do not 
express estrogen receptor, progesterone receptor and HER2 (as called triple-
negative), are still difficult to be treated as most therapies target one of the three 
receptors. Obviously, the discovery of tumor biomarkers and the subsequent 
development of novel antineoplastic agents will benefit thousands of cancer 
patients worldwide. 
 Persistent activation of STAT3 has been reported in most human cancers 
including ovarian, endometrial, cervical, breast, colon, pancreatic, lung, brain, 
renal, and prostate cancers, head and neck squamous cell carcinoma, glioma, 
melanoma, lymphomas and leukemia (56). STAT3 thus serves as a clinically 
useful biomarker for metastatic tumors with advanced disease stage. For instance, 
early-stage patients with non-small cell lung cancer (NSCLC) have higher long-
term survival after surgery; however, approximately 75% of NSCLC patients are 
diagnosed in advanced stages (57). A meta-analysis based on 17 retrospective 
trials has recently revealed that high STAT3 and phospho-STAT3 expression is of 
prognostic significance for survival of NSCLC patients (58). STAT3 and phospho-
STAT3 expression are significantly higher in NSCLC patients with poorly 
differentiated carcinoma, advanced disease stage and lymph node metastasis. 
Thus, high STAT3 or phospho-STAT3 expression is an important predictor of poor 
prognosis among patients with NSCLC. Moreover, Positive STAT3 expression was 
observed in 69.2% of breast tumors (59). And phospho-STAT3 was significantly 
higher in invasive carcinoma than in nonneoplastic tissue (60). Obviously, STAT3 
is an important biomarker of progression in diverse cancers. 
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STAT3 is also an attractive therapeutic target for cancers. The mainstay of 
cancer treatment is surgery when the tumor is localized, followed by radiotherapy 
and chemotherapy. Multiple chemotherapeutic agents are used in combination to 
treat patients with cancers, including cyclophosphamide, methotrexate, 5-
fluorouracil, doxorubicin, paclitaxel, cisplatin, etc. Targeted therapies are also used 
to fight cancers including antibodies/antagonists for hormones/receptors, signaling 
transduction inhibitors and angiogenesis inhibitors. By focusing on molecular and 
cellular targets that are specific to cancers, targeted cancer therapy may be more 
effective than other types of treatment, such as chemotherapy and radiotherapy, 
and less harmful to normal cells. Targeted agents permit the design of more 
rational therapeutic regimens for cancers. Inhibition of STAT3 has been shown to 
reduce tumor growth and metastasis in diverse studies as a common feature of 
many cancers is their dependence for survival on the constitutive activation of 
STAT3 (56, 61, 62). Given that the selection of first-line chemotherapy for cancers 
is complex due to the inherent biologic heterogeneity of the disease, the 
development of specific STAT3 inhibitors may potentially provide more options for 
clinical cancer therapy. 
Additionally, constitutive STAT3 signaling causes resistance to 
chemotherapy in patients (63). As STAT3 is involved in IFN and EGF signaling, 
the increased level of STAT3 phosphorylation is also associated with the clinical 
effectiveness of targeted therapy to INF-α and EGF in cancer patients (64-67). 
STAT3 is thus a prognostic factor that can predict the patient’s responses to 
related treatments. Moreover, recent studies have found that STAT3 is a 
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determinant of chemoresistance and is associated with tumor recurrence in a large 
number of solid malignancies (68). STAT3 promotes transcription of crucial 
regulators of cell cycle progression and anti-apoptosis. Persistent activation of 
STAT3 may lead to protection against cytotoxic agents in cancers. Thus, the 
pharmacological inhibition of STAT3 may be also a promising therapeutic strategy 
for the management of chemoresistance in cancers. 
Overall, STAT3 has emerged as a promising drug target for cancer 
treatment. 
 
E. Strategies to inhibit aberrant STAT3 signaling 
A variety of STAT3 inhibitors have been previously identified (56, 61, 62). 
The current STAT3 inhibitors usually (1) inhibit STAT3 activation; (2) disrupt 
STAT3 dimerization; (3) block the binding of STAT3 to DNA. 
The first proof-of-concept approach was derived from peptidic and 
peptidomimetic inhibitors mimicking the sequence that binds to the SH2 domain of 
STAT3 to disrupt its dimerization. These inhibitors consist of small peptides 
PpYLKTK, pYLPQTV and mimetics ISS 610 (69-71). However, the feature of 
peptides determines their low membrane permeability, low stability and poor 
bioavailability. Although ISS 610 exhibits improved activity on inhibition of STAT3 
and selectivity over STAT1 and STAT5 in in vitro DNA-binding assays, its 
intracellular activity remains low as it cannot be efficiently taken up by cells. 
Computational approaches and assay-based screening were then used to identify 
a number of small molecule inhibitors targeting the SH2 domain, e.g. STA-21, 
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stattic, S3I-201, S3I-M2001, catechol containing compounds, FLLL32 and LLL-12 
(72-81). These small molecule inhibitors appear to block the formation of STAT3 
dimers and inhibit proliferation and survival of cancer cells harboring constitutive 
STAT3 signaling. Both peptide and non-peptide inhibitors demonstrate the 
feasibility of targeting the SH2 domain and dimerization of STAT3. However, most 
of them have limited clinical development because of their moderate activities at 
medium to high micromolar levels. Additionally, it has been shown recently that 
STAT3 involves in oncogenesis and transcriptional regulation in the absence of 
tyrosine phosphorylation (82-85). Thus disruption of STAT3 dimerization may be 
not enough to inhibit aberrant STAT3 signaling.  
As the transcriptional activity of STAT3 requires physical interaction 
between STAT3 and the promoter regions of responsive genes, DBD is also a 
potential drug target. Galiellalactone, peptide aptamers, flavopiridol and a class of 
platinum (IV) compounds including IS3295, CPA-1, CPA-7 and platinum (V) 
tetrachloride were found to interfere with STAT3 binding to DNA and inhibit STAT3-
dependent gene transcription, resulting in the induction of cell growth inhibition and 
apoptosis in human breast, lung and prostate cancer cells (86-92). Some of these 
inhibitors have been evaluated in animal models and they appear to reduce growth 
of xenograft tumors. All these findings suggest that DBD is likely druggable, 
however, specificity may be a difficult problem to solve. For example, a small 
molecule compound NSC-368262 (C48) has been recently identified as a STAT3 
inhibitor that alkylates cysteine 468 at the DNA-binding interface, but mixing 
glutathione with C48 confirmed alkylation of the thiol group of glutathione by C48, 
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indicating it may alkylate every surface-exposed cysteine residues (93). On the 
other hand, decoy oligodeoxynucleotides (ODNs) are also a novel strategy by 
mimicking STAT3 specific DNA-binding sequence and competing for binding to 
STAT3, leading to suppression of STAT3-mediated gene transcription (94-98). 
Decoy ODNs usually represent preferable specificity over other modalities, 
however, an important issue is a suitable bioavailability profile for these biological 
agents. Amazingly, the first human trial of a STAT3 decoy ODN in head and neck 
tumors has been successfully completed (99). These findings show that STAT3 
decoy ODN can be modified to enable systemic delivery and be used to inhibit 
tumor growth through intravenous injection. 
STAT3 signaling can be also indirectly modulated by targeting the upstream 
components of STAT3 activation. These inhibitors include JAK inhibitors such as 
AG490, resveratrol, WP1066, AZD1480 and TG101209, receptor tyrosine kinase 
inhibitor such as tyrphostins and Src kinase inhibitor such as indirubin (100-107). 
Moreover, targeting upstream factors for STAT3 expression such as antisense 
oligonucleotides have been considered and tested (108, 109). Due to implication 
of other pathways, these inhibitors may be limited to specifically inhibit STAT3 
signaling. 
In summary, the preclinical investigation of STAT3 inhibitors provides a 
great foundation rationale for further development of novel anti-cancer drugs. The 
progress in studying these candidate inhibitors imply that STAT3 is a druggable 
target in human cancers. However, none of these STAT3 inhibitors has been 
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approved for clinical use. More studies are clearly needed for further development 
of clinically available agents. 
 
F. Specific aims of the present work 
It is well recognized that STAT3 is an attractive target for drug development. 
The major problems in successful development of STAT3 inhibitors consist of low 
biological activity, low membrane permeability and low specificity. An ideal STAT3 
inhibitor should target STAT3 but not affect upstream components or other STAT 
family members. As reviewed above, the peptidic and peptidomimetic inhibitors 
are more easily to be designed and developed but have low membrane 
permeability due to the feature of peptides. Although small molecule compounds 
targeting SH2 domain show enhanced membrane permeability, the clinical 
development has been slow. No inhibitors targeting SH2 domain has entered 
clinical trials so far and unphosphorylated STAT3 also plays an important role in 
oncogenesis (82-85). Thus, inhibiting DNA binding is a promising strategy as the 
first clinical trial of STAT3 decoy ODN was successful (99). Although STAT3 ODN 
can be modified to enable systemic delivery, intravenous injection is not a user-
friendly route of administration. 
Based on the current progress of STAT3 inhibitors as discussed above, my 
study was designed to identify small molecule compounds targeting the DBD of 
STAT3 and to investigate the mechanism of the candidate compounds for 
development of effective and specific STAT3 inhibitors targeting DBD. The first 
aim is to identify small molecule compounds targeting the DBD of STAT3 using 
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structure-based virtual compound screening and STAT3-dependent luciferase 
activity assay as well as to verify the effects and specificity of the candidate 
compounds on STAT3 protein. Structure-activity relationship analysis was 
performed to optimize the chemical structure to achieve the optimal biological 
activity and specificity. The anti-tumor effects of the candidate compounds were 
investigated, including cell survival, apoptosis, cell migration and invasion. Finally, 
the in vivo efficacy of the most promising compound was evaluated in a mouse 
xenograft tumor model. 
The second aim is to investigate the detailed mechanism of the candidate 
compounds on inhibition of aberrant STAT3 signaling. Specifically, the effects on 
STAT3 signaling pathway were assessed to verify the efficacy and specificity of 
the compounds, e.g. the activation of STAT3, the dimerization of STAT3, the 
binding of STAT3 to DNA and the expression of STAT3 downstream targets. 
The outcome from this study would lead to a better understanding of 
development of STAT3 inhibitors targeting the DBD and thus help develop better 
antineoplastic drugs and therapeutic regimens for cancer treatment.  
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II. Materials and Methods 
A. Materials 
Cell culture mediums Dulbecco's Modification of Eagle's Medium (DMEM, 
Catalog No.: 10-013-CV), RPMI-1640 (Catalog No.: 10-040-CV), DMEM/Ham's F-
12 50/50 Mix (Catalog No.: 11320-033) and Opti-MEM (Catalog No.: 51985-034) 
as well as cell culture materials including fetal bovine serum (FBS; Catalog No.: 
104375), equine serum (Catalog No.: 26050), trypsin-versene mixture (Catalog 
No.: 17-161-E) and penicillin/streptomycin (Catalog No.: 17-602-E) were 
purchased from Corning cellgro (Manassas, VA), Life Technologies (Grand Island, 
NY) or Lonza (Walkersville, MD). Luciferase Assay System (Catalog No.: E4030), 
Dual-Luciferase® Reporter Assay System (Catalog No.: E1910), GSH-GloTM 
Glutathione Assay System (Catalog No.: V6911), T4 polynucleotide kinase 
(Catalog No.: M410A) and its buffer (Catalog No.: C131B) were obtained from 
Promega (Madison, WI). Metafectene® transfection reagent (Catalog No.: T020-
1.0) was purchased from Biontex Laboratories GmbH (Martinsried, Germany). 
Quick Spin Columns (Catalog No.: 1522981) and Cell Death Detection ELISAPLUS 
Photometric Enzyme Immunoassay Kit (Catalog No.: 1774425) were purchased 
from Roche Diagnostics GmbH (Mannheim, Germany). BioCoatTM MatrigelTM 
Invasion Chambers (Catalog No.: 354480) came from BD Biosciences (Bedford, 
MA). Human insulin solution (Catalog No.: I9278-5ML), human EGF (Catalog No.: 
E5036-200UG), protease inhibitor cocktail (Catalog No.: P8340), fibronectin 
lyophilized powder (Catalog No.: F2006) and His-tagged human recombinant 
STAT3 protein (Catalog No.: SRP5374-20UG) were obtained from Sigma-Aldrich 
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(St. Louis, MO). Bio-Rad Protein Assay Dye Reagent (Catalog No.: 500-0006) and 
iScriptTM cDNA Synthesis Kit (Catalog No.: 170-8891) were purchased from Bio-
Rad Laboratories (Hercules, CA). ImmobilonTM Polyvinylidene Difluoride (PVDF) 
Transfer Membranes (Catalog No.: IPVH00010), Chromatin Immunoprecipitation 
Assay Kit (Catalog No.:17-295) and purified rabbit IgG (Catalog No.: PP64B) came 
from EMD Millipore (Billerica, MA). EAH-SepharoseTM 4B (Catalog No.: 17-0569-
01), CNBr-activated SepharoseTM 4B (Catalog No.: 71-7086-00) and AmershamTM 
ECL Western Blotting Detection Reagent (Catalog No.: RPN2106) were obtained 
from GE Healthcare (Uppsala, Sweden). SuperSignal West Dura 
Chemiluminescent Substrate (Catalog No.: 34075) was purchased from Pierce 
(Rockford, IL). RNeasy® Mini Kit (Catalog No.: 74104) was obtained from Qiagen 
(Valencia, CA). SYBR® Green PCR Master Mix (Catalog No.: 4309155) came from 
Applied Biosystems (Warrington, UK). Hot Rod Chemistry® formulation screening 
kit 1 and 2 (Catalog No.: HRC-K1 and HRC-K2) were purchased from Pharmatek 
Laboratories (San Diego, CA). ImmPRESSTM reagent kit (Catalog No.: MP-7401 
and MP-7405) and ImmPACTTM DAB peroxidase substrate kit (Catalog No.: SK-
4105) were obtained from Vector Laboratories (Burlingame, CA). 
Antibodies against STAT3 (Catalog No.: sc-482x), STAT1 (Catalog No.: sc-
346x), cyclin D1 (Catalog No.: sc-246), MMP-2 (Catalog No.: sc-10736), MMP-9 
(Catalog No.: sc-10737), VEGF (Catalog No.: sc-152) and twist (Catalog No.: sc-
81417) were purchased from Santa Cruz (Dallas, TX). Antibodies against STAT3 
(Catalog No.: 9139), phospho-STAT3 (Catalog No.: 9145), survivin (Catalog No.: 
2802 and 2808), histone H2A (Catalog No.: 2578) and histone H3 (Catalog No.: 
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9715) were obtained from Cell Signaling Technology (Danvers, MA). Monoclonal 
antibodies against FLAG (Catalog No.: F3165), α-Tubulin (Catalog No.: T9026) 
and β-actin (Catalog No.: A5316) as well as horseradish peroxidase-conjugated 
secondary antibodies to mouse IgG (Catalog No.: A9309) or rabbit IgG (Catalog 
No.: A9169) came from Sigma-Aldrich.  
All other chemicals were of molecular biology grade from Sigma-Aldrich or 
Fisher Scientific (Chicago, IL). 
 
B. Cell lines and culture 
Human lung cancer cell line A549, human breast cancer cell lines MDA-
MB-231, MDA-MB-231-STAT3 (MDA-MB-231-STAT3 cells stably cloned with 
STAT3-dependent luciferase reporter were obtained from Dr. Jiayuh Lin at Ohio 
State University) and MDA-MB-468 and human normal lung fibroblast cell line 
IMR90 were cultured in DMEM, supplemented with 10% FBS and appropriate 
antibiotics (100 units/mL penicillin and 100 μg/mL streptomycin) in a 37°C 
humidified atmosphere containing 5% CO2. Human lung cancer cell line H1299 
was maintained in RPMI-1640 medium containing 10% FBS and appropriate 
antibiotics at 37°C with 5% CO2. Human normal breast epithelial cell line MCF10A1 
was cultured in DMEM/Ham's F-12 50/50 Mix with 10% equine serum, 10 μg/mL 
insulin, 25 ng/mL EGF, 500 ng/mL hydrocortisone, 100 ng/mL cholera toxin and 
appropriate antibiotics at 37°C with 5% CO2. 
 
C. Structure-based virtual compound screening 
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(Courtesy of Dr. Jing-Yuan Liu) 
To identify the potential small molecule compounds that can directly disrupt 
the interaction between STAT3 and its DNA substrates, the crystal structure of 
STAT3β-DNA complex was retrieved from Protein Data Bank 
(http://www.rcsb.org/pdb; PDB code: 1BG1). The DNA in the crystal structure was 
removed and the protein chain was prepared for molecular docking. The 
coordinates of DBD and Linker domain (residues 320-550), which are directly 
involved in DNA binding, were applied to the calculation. The DNA-binding groove 
consisting of residues 329-332, 340-346, 406-412 and 465-468 was chosen as the 
targeting area for molecular docking. Molecular surface was computed using the 
software Distributed Molecular Surface. Partial charges and protons were added 
to the protein by DockPrep module of Chimera (110). 200,000 small molecule 
virtual compounds obtained from ChemDiv library (San Diego, CA) were screened 
using the molecular docking program DOCK 6.0 (111). The docking of each 
compound was scored with the DOCK GRID scoring function. The 1,000 top-
scoring compounds were then analyzed and re-scored using the AMBER scoring 
function of DOCK 6.0 package (112).  
The top-scoring compounds were also docked onto the DBD of STAT1 
(PDB code: 1BF5). Compounds scored well with STAT1 were eliminated and the 
remaining compounds with poor scores for STAT1 were further clustered using the 
software Molecular Operating Environment and visually examined using Chimera 
ViewDock function. A total of 100 compounds were finally selected based on the 
combination of GRID and AMBER scores, drug likeness (Lipinski’s rule of five) as 
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well as based on the consideration of maximizing compounds from different 
clusters. 
 
D. STAT3-dependent luciferase reporter assay 
MDA-MB-231-STAT3 cell line stably transfected with a high level of STAT3-
dependent luciferase reporter was used to screen the potential STAT3 inhibitors 
as described previously (74). Cells were seeded at 5×104 cells per well in a 12-
well plate. Next day, cells were exposed to 0.1% dimethyl sulfoxide (DMSO) 
vehicle control or the candidate compounds at 20 µM for 48 hours and the 
luciferase activity was then measured by Luciferase Assay System according to 
the manufacturer’s instructions. In brief, growth medium was removed from 
cultured cells after treatment followed by washing with 1× phosphate buffered 
saline (PBS; 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO4, pH 7.4) 
three times. Cells were dispensed in 200 µL of 1× cell culture lysis reagent 
provided by the kit and then lysed by three freeze-thaw cycles (incubation in dry 
ice-ethanol bath for 2 minutes followed by incubation at 37°C for 10 minutes). Cell 
suspensions were subjected to centrifugation at 13,000 rpm for 2 minutes. Then 5 
µL of supernatant was mixed with 25 µL of luciferase assay reagent for 
measurement of the luminescence by using Berthold Detection Systems Sirius 
Luminometer (Titertek-Berthold, Germany) and the luciferase activity levels were 
finally normalized to total protein content measured using Bio-Rad Protein Assay 
Dye Reagent. 
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To verify the specificity of STAT3-dependent luciferase reporter, a 
luciferase reporter driven by p27 promoter containing no STAT3-binding site was 
used as a negative control (113). H1299 cells were transiently transfected with a 
p27 promoter-driven Firefly reporter plasmid and a transfection control Renilla 
reporter plasmid using Metafectene® transfection reagent according to the 
manufacturer’s suggestions followed by reseeding in a 24-well plate with 5×104 
cells per well. After 24 hours, the transfected cells were exposed to the candidate 
compounds for 48 hours. The p27 promoter-driven Firefly reporter activity was 
determined by using Dual-Luciferase® Reporter Assay System and then 
normalized to the co-transfected Renilla, following the manufacturer’s instructions. 
 
E. Molecular dynamics simulation and calculation of binding free energy 
(Courtesy of Dr. Jing-Yuan Liu) 
To verify the preference of candidate compounds on STAT3 over STAT1, 
the binding free energy of inS3-54 to STAT3 or STAT1 was computed by 3-ns 
molecular dynamics simulation followed by Born/surface area (GBSA) energy 
analysis. Briefly, a total of 20 snapshots were collected from the production 
trajectory for MM-GBSA free energy calculations using the formula ∆Gbind = Gcomplex 
- GSTAT - GinS3-54, where G = Gsolute + Gsolvent. 
 
F. Electrophoretic mobility shift assay 
As the compounds were designed to target the DBD of STAT3, 
electrophoretic mobility shift assay (EMSA) was used to determine the inhibitory 
23 
effects of compounds on DNA-binding activity of STAT3 and STAT1. For 
preparation of cell lysates, 4×106 H1299 cells were plated in a 150-mm tissue 
culture dish for 24 hours, followed by transient transfection with FLAG-tagged 
constitutively dimerizable STAT3c or STAT1 expression construct using 
Metafectene® transfection reagent according to the supplier’s instructions. 48 
hours after transfection, cells were harvested and re-suspended in hypertonic 
buffer (20 mM HEPES·KOH, pH 7.9, 1.5 mM MgCl2, 420 mM KCl, 0.2 mM EDTA, 
0.5 mM DTT, 1 mM PMSF, 1 mM NaVO3, 20 mM NaF, 20% glycerol, 0.01 mM 
NaP2O7) as well as centrifuged at 13,000 g for 10 minutes at 4°C after three freeze-
thaw cycles (dry ice-ethanol bath for 2 minutes and 37°C for 10 minutes). The 
supernatant was collected, aliquoted and stored at -70°C. For preparation of [32P]-
labeled sis-inducible element (SIE) probe, 40 ng of unlabeled SIE probe (5’-
AGCTTCATTTCCCGTAAATCCCTA-3’) was incubated at 37°C for 45 minutes 
with 50 μCi γ-32P-adenosine triphosphate (ATP) and 10 units of T4 polynucleotide 
kinase in 10 μL kinase reaction buffer. Radiolabeled probe was then purified by 
Quick Spin Column to remove free nucleotides. The purified probe was then 
qualified by using Beckman Coulter LS 6500 Multi-purpose Scintillation Counter 
(Beckman Coulter, Brea, CA), diluted to 5x104 cpm/μL and stored at -70°C. For 
EMSA, 20 µg of cell lysate was pre-incubated with indicated compounds for 30 
minutes at room temperature in the binding buffer (10 mM HEPES·KOH, pH 7.9, 
0.1 µg/µL poly(dI·dC), 50 mM KCl, 10% glycerol, 0.05 µg/µL BSA, 1 mM DTT and 
0.2 mM PMSF) before adding 5×104 cpm [32P]-labeled SIE probe. For supershift 
and competition, 4 µL specific antibody against STAT3 or STAT1 or 100-fold 
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excess non-radioactive SIE probe was added to the reaction mixture and 
incubated for 30 minutes before adding the radiolabeled probe. All mixture 
reactions were incubated for 20 minutes at room temperature and then separated 
on 6% native polyacrylamide gel in 0.25× TBE buffer (22.5 mM Tris·boric acid, pH 
8.3, 0.5 mM EDTA). Radiolabeled bands were finally visualized by 
autoradiography. 
 
G. Preparation of inS3-54-conjugated EAH-Sepharose 4B and pull down 
assay 
EAH-Sepharose 4B containing 7-11 μmol conjugated amino group in 1 mL 
of drained gel  was used to conjugate inS3-54 containing carboxyl group through 
the carbodiimide coupling method according to manufacturer’s instructions. For 
the coupling reaction, 200 μL EAH-Sepharose 4B gels were washed on a sintered 
glass filter with 16 mL of distilled water adjusted to pH 4.5 with HCl, followed by 16 
mL of 0.5 M NaCl. (±) 2 mg inS3-54 or irrelevant compound (C5) dissolved in 240 
μL of 50% (v/v) dimethylformamide solution was mixed with drained EAH-
Sepharose 4B. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was added 
to EAH-Sepharose 4B solution as a catalyst for the coupling reaction at a final 
concentration of 0.1 M. The reaction mixtures were rotated for 24 hours at 4°C. 
After the coupling reaction had finished, the gels were washed with 16 mL of 50% 
(v/v) dimethylformamide to remove free compounds and the remaining active 
groups were blocked in a further carbodiimide reaction with 1 M acetic acid under 
catalysis of 0.1 M EDC. The gels were then washed alternatively with 0.5 M NaCl 
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in 0.1 M Tris·HCl (pH 8.3) and 0.5 M NaCl in 0.1 M sodium acetate/acetic acid 
buffer (pH 4.0) for at least three cycles. The gels were further washed with double 
distilled water and stored at 4°C in binding buffer (10 mM MES/NaOH, pH 6.5, 150 
mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM KCl, 0.5% NP-40) used for the following 
pull-down assay. The coupling efficacy was verified by monitoring whether the 
transparent beads turn color after coupled with the orange (inS3-54) or yellow (C5) 
compounds. 
For pull-down assay, inS3-54-conjugated beads and two kinds of control 
beads (vehicle control and irrelevant compound C5) equilibrated with binding 
buffer were blocked with 10% non-fat milk in binding buffer containing 2 mM PMSF 
and 1:1000 diluted protease inhibitor cocktail followed by incubation with 120 µg 
total lysate of H1299 cells harboring FLAG-STAT3c in the same buffer at 37°C for 
1 hour. The unbound proteins were removed by washing with the binding buffer 
seven times and the proteins bound to inS3-54-conjugated beads were directly 
separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) followed by either gel silver staining or immunoblotting with 
respective antibodies. The bound proteins were also eluted from the beads by 
excess free inS3-54 followed by SDS-PAGE and Western blot analysis. For 
competition analysis, cell lysates were pre-incubated with DMSO vehicle, 10 µM 
inS3-54 or C5 at 37°C for 1 hour prior to incubation with inS3-54-conjugated beads. 
To investigate the potential direct interaction between inS3-54 and STAT3, 1 µg of 
commercial human recombinant STAT3 protein with His-tag was also applied to 
pull down assay following the same procedure. 
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H. Preparation of A26-conjugated CNBr-activated Sepharose 4B and pull 
down assay 
CNBr-activated Sepharose 4B was used for coupling the compound A26 
containing imino group by the cyanogen bromide method according to the 
manufacturer’s instructions. For the coupling reaction, 1 g lyophilized CNBr-
activated Sepharose 4B was dissolved in 3.5 mL of 1 mM HCl and washed with 
200 mL of 1 mM HCl on a sintered glass filter. (±) 10 μmoles of A26 or inactive 
compound (PHP) was dissolved in 5 mL of coupling buffer (0.1 M NaHCO3, pH 8.3, 
0.5 M NaCl) and mixed with the prepared CNBr-activated Sepharose 4B in a 
stoppered vessel, followed by rotation overnight at 4°C. After the coupling reaction, 
the excess compounds were washed with at least 25 mL of coupling buffer. Any 
remaining active groups were further blocked with 0.1 M Tris·HCl, pH 8.0 overnight 
at 4°C. Finally, the gels were washed with at least three cycles of alternating pH 
with 0.1 M sodium acetate/acetic acid, pH 4.0 containing 0.5 M NaCl and 0.1 M 
Tris·HCl, pH 8.0 containing 0.5 M NaCl and stored at 4°C in 0.1 M Tris·HCl, pH 
8.0 containing 0.5 M NaCl. Since A26 is yellow and PHP is pale yellow in color, 
the conjugation of A26 or PHP to CNBr-activated Sepharose 4B can be verified by 
monitoring the change in color of the beads. 
For pull-down assay, A26-conjugated and two kinds of control beads 
(DMSO vehicle control and irrelevant compound PHP) equilibrated with washing 
buffer (20 mM Tris-HCl, pH 8.0, 75 mM KCl, 1 mM EDTA, 15% glycerol, 0.5% NP-
40) were blocked with 10% non-fat milk in the binding buffer (20 mM Tris-HCl, pH 
8.0, 150 mM KCl, 1 mM EDTA, 15% glycerol, 0.5% NP-40, 0.2 mM PMSF and 
27 
1:1000 diluted protease inhibitor cocktail) followed by incubation with 120 µg total 
lysate of H1299 cells transfected with FLAG-STAT3 in the same buffer both at 
37°C for 1 hour. The unbound proteins were removed by washing seven times with 
the washing buffer and the bound proteins were subjected to SDS-PAGE followed 
by analysis of FLAG-STAT3c using Western blot analysis. For competition analysis, 
cell lysates were pre-incubated with DMSO vehicle, 10 µM inS3-54 analogues or 
PHP at 37°C for 1 hour prior to incubation with A26-conjugated beads. 
 
I. Glutathione assay 
Glutathione served as a substrate to determine whether inS3-54 or its 
analogue A18 might act as an alkylating agent to surface-exposed cysteine as 
described previously (93). It is assumed that an agent that alkylates cysteine 
residues may also alkylate glutathione via its thiol group. To determine whether or 
not glutathione was alkylated by the compounds, A549 or MDA-MB-231 cells were 
exposed to DMSO vehicle or indicated compounds for 48 hours. Following 
treatment, the glutathione level was measured using GSH-GloTM Glutathione 
Assay Kit which provides a luminescence-based assay for the detection and 
quantification of glutathione. Briefly, 5×103 cells were harvested and dispensed in 
50 μL of GSH-GloTM reagent containing luciferin-NT substrate and glutathione S-
transferase diluted in GSH-GloTM reaction buffer, followed by incubation at room 
temperature for 30 minutes. As shown in Figure 3, luciferin is generated from the 
luminogenic luciferin-NT substrate, catalyzed by glutathione S-transferase in the 
presence of glutathione. Then, reaction mixtures were further incubated for 15 
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minutes with 100 μL/well of luciferin detection reagent which simultaneously stops 
the previous reaction and initiate a luminescent signal. Finally, the luminescence 
produced was read by Berthold Detection Systems Sirius Luminometer. The 
luminescent signal produced is directly proportional to the amount of glutathione 
in cells. The relative level of glutathione was compared with that of DMSO vehicle 
control which did not receive drug treatment. Iodoacetamide (IAA), which binds 
covalently to the thiol group of cysteine, was used as a positive control.  
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Figure 3. Schematic diagram of GSH-GloTM glutathione assay. 
The assay is based on the conversion of a luciferin derivative into luciferin in the 
presence of glutathione, catalyzed by glutathione S-transferase. The signal 
generated in a coupled reaction with firefly luciferase is proportional to the amount 
of glutathione present in the sample. GSH: glutathione; GST; glutathione S-
transferase; GS-R: glutathione derivative. The figure is adapted from GSH-GloTM 
Glutathione Assay Technical Manual provided by the manufacturer.  
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J. Cytotoxicity assay 
Cytotoxicity of indicated compounds to cancer cells was determined using 
sulforhodamine B (SRB) colorimetric assay as previously described (114, 115). 
1×103 cells/well were plated in a 96-well plate overnight. Cells were then treated 
with indicated compounds for 72 hours. After treatment, the culture medium was 
removed and the cells were fixed and stained by addition of 0.4% (w/v) SRB in 1% 
acetic acid solution followed by incubation at room temperature for 20 minutes. 
The plate was washed four times with 1% acetic acid to remove the unbound SRB 
and air-dried overnight at room temperature. The bound SRB was then solubilized 
in 100 μL of 10 mM unbuffered Tris·base. Optical density (OD) was determined at 
570 nm using BioTek Synergy H1 Hybrid Microplate Reader (BioTek, Winooski, 
VT). Cell viability was determined as compared with vehicle control (0.1% DMSO) 
and calculated using the following formula: survival (%) = ODTreatment/ODDMSO × 
100%. The cell survival curve was plotted by the survival fractions on y-axis against 
the logarithmic concentrations on x-axis. IC50 of indicated compounds for each cell 
line was finally computed using the GraphPad Prism software (GraphPad Software, 
La Jolla, CA). 
 
K. Enzyme-linked immunosorbent assay for quantification of apoptosis 
To investigate the potential contribution of indicated compounds to 
apoptosis, Cell Death Detection ELISAPLUS Photometric Enzyme Immunoassay 
was used for the quantitative determination of cytoplasmic histone-associated 
DNA fragments after induced cell death as we previously described (115). Briefly, 
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exponentially growing A549 or MDA-MB-231 cells were seeded in a 12-well plate 
at 7.5×104 cells/well. 24 hours after plating, cells were exposed to various 
compounds under indicated conditions. Growth medium was removed from 
cultured cells after treatment followed by washing with 1× PBS one time. 1×104 
cells were then collected and resuspended in 200 μL of lysis buffer provided by 
the kit, followed by incubation at room temperature for 30 minutes. Cell lysates 
were centrifuged at 200 g for 10 minutes. As shown in Figure 4, 20 μL of 
supernatant for each sample was placed into a streptavidin-coated microplate, 
followed by adding a mixture of biotin-conjugated anti-histone antibody and 
horseradish peroxidase-conjugated anti-DNA antibody as well as incubating at 
room temperature for 2 hours. During the incubation interval, nucleosomes were 
captured via their histone components by the biotin-conjugated anti-histone 
antibody, while binding to the streptavidin-coated microplate. Simultaneously, the 
DNA fragments of nucleosomes were detected by anti-DNA antibody. After 
removal of unbound antibodies by a washing step, the amount of nucleosomes 
was quantified by the peroxidase retained in the immunocomplex with ABTS as a 
substrate. The relative level of DNA fragmentation was compared with that of 
DMSO vehicle control that did not receive drug treatment.  
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Figure 4. Schematic diagram of apoptosis ELISA assay. 
The assay is used for the quantitative in vitro determination of cytoplasmic histone-
associated DNA fragments after induced cell death. The figure is adapted from 
Cell Death Detection ELISAPLUS Photometric Enzyme Immunoassay Kit 
Instructions provided by the manufacturer.  
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L. Hematopoietic progenitor cell colony formation assay 
(Courtesy of Dr. Hal Broxmeyer) 
Hematopoietic progenitor cell colony formation assay was performed as 
previously described (116, 117). A STAT3 allele in which exons 18–20 were 
flanked by loxP sequences was generated. Removal of exons 18–20, which 
encode the SH2 domain of STAT3, was expected to eliminate the function of the 
protein. A mouse strain (C57BL/6) for tissue-specific gene deletion where Cre 
expression is driven by a TIE2 gene promoter/enhancer cassette was used to 
generate the unique strain of mice with tissue-specific deletion of STAT3 during 
hematopoiesis. The TIE2 gene promoter triggered Cre expression in bone marrow 
and endothelial cells. In two steps of breeding STAT3-loxP with Tie2-Cre, the mice 
that are homozygous for STAT3-loxP and Tie2-Cre+ were obtained as the 
conditional STAT3 knock-out mice. 5×104/mL STAT3+/+ and STAT3-/- mouse bone 
marrow cells were then isolated and stimulated in vitro with 1 unit/mL recombinant 
human erythropoietin, 50 ng/mL recombinant mouse stem cell factor, 5% (v/v) 
pokeweed mitogen mouse spleen cell conditioned medium and 0.1 mM hemin in 
the presence of DMSO vehicle control or indicated compounds. Colonies were 
scored 7 days after incubation at 5% CO2 and lowered (5%) O2. 
 
M. Cell migration assay 
Wound filling assay was used to determine the inhibitory effect of indicated 
compounds on cell migration as described previously (118). Briefly, 1×105 
cells/well A549 or MDA-MB-231 cells were seeded in a 6-well plate. 24 hours after 
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plating, cells reached 90%~100% confluence as a monolayer. 200-μL pipette tip 
was used to scratch the monolayer across the center of each well. After scratching, 
cells were gently washed one time with fresh medium to remove the detached cells 
and then incubated with or without the treatment of indicated compounds. The 
wound filling process over a 24-hour period was monitored and photographed at 
different time intervals (0, 6, 12 and 24 hours following treatment) with a 
magnification of 40× using Zeiss Axiovert 25 Microscopic Camera System (Carl 
Zeiss, Göttingen, Germany) as well as quantified by measuring the remaining gap 
between two migrating edges in Photoshop software. The migration rate on various 
time intervals was calculated using the following formula: migration rate (%) = 
(mean distance between both edges at 0 hr - mean distance between both edges 
at T hrs)/ mean distance between both edges at 0 hr × 100%. 
 
N. Cell invasion assay 
To determine the inhibitory effect of indicated compounds on cell invasion, 
cell invasion assay was carried out using BioCoatTM MatrigelTM Invasion Chambers 
following the manufacturer’s instructions. The package was firstly removed from -
20°C storage and pre-coated with 250 μL of 30 µg/µL fibronectin per well overnight 
at 4°C. Matrigel inserts were then pre-warmed in serum-free medium at 37°C for 
1 hour. 1.25×105 cells per well were plated in the upper compartments of 24-well 
Matrigel invasion chambers with serum-free medium in the absence or presence 
of indicated compounds. Medium containing 10% FBS in the lower chambers 
serves as a chemo-attractant. The Matrigel™ matrix provides a true barrier to non-
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invasive cells while presenting an appropriate protein structure for invading cells 
to penetrate before passing through the 8-μm pores on the chamber membrane. 
After incubation at 37°C for 6 or 24 hours, the non-invading cells attached on the 
upper surface of the membrane were gently removed with a cotton swab. Cells 
invading to the undersurface of the membrane were stained with a fixative/staining 
solution (0.1% crystal violet, 1% formalin, 20% ethanol), photographed and 
counted for invasive cell number in 10 randomly selected fields for each treatment 
using Zeiss Axiovert 25 Microscopic Camera System. The invasion rates of 
indicated compounds were quantified by invasive cell numbers compared to 
DMSO control. 
 
O. Western blot analysis 
Western blot analysis was used to determine the protein expression level. 
1×106 MDA-MB-231 or A549 cells were seeded in 100-mm tissue culture dishes 
and exposed to various treatments under appropriate conditions. After treatment, 
cells were harvested and suspended in lysis buffer containing 50 mM Tris·HCl, pH 
7.4, 150 mM NaCl, 0.5% NP-40, 20 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 2 mM 
PMSF and 1 mM DTT followed by incubation on ice for 10 minutes. The cell lysates 
were sonicated briefly (3 cycles of 7 seconds with 40% amplitude) and centrifuged 
at 13,000 rpm for 20 minutes at 4°C. The soluble supernatants were collected and 
their protein concentrations were measured using Bio-Rad Protein Assay Dye 
Reagent. 
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Equivalent amount of cell lysate protein (40~60 μg) was separated on 
10%~15% SDS-PAGE and transferred onto a PVDF membrane. The blot was then 
blocked with 5% non-fat milk in PBS containing 0.1% Tween-20 at room 
temperature for 1 hour and probed with the desired primary antibody to specific 
protein (diluted according to the manufacturer’s instructions) at room temperature 
for 2 hours or at 4°C overnight. Subsequently, the blot was incubated with 
appropriate horseradish peroxidase-conjugated secondary antibody and the 
immunoreactive protein bands were visualized using AmershamTM ECL Western 
Blotting Detection Reagent or SuperSignal West Dura Chemiluminescent 
Substrate and captured by X-ray film or FluoChemTM HD2 Imaging System 
(ProteinSimple, Santa Clara, CA). The relative protein levels were determined by 
the density of Western blot bands as measured by Image J software (National 
Institutes of Health) and normalized against the internal control β-actin. 
 
P. Real-time polymerase chain reaction 
Real-time polymerase chain reaction (PCR) was used to determine the 
mRNA expression level in tumor cells following treatment. Total RNAs were 
isolated from cultured cells using RNeasy® Mini Kit according to the manufacturer’s 
instructions. 4 μg of total RNAs were reverse-transcribed using iScriptTM cDNA 
Synthesis Kit. Primers used for real-time PCR were shown in Table 2. Real-time 
PCR was performed with SYBR® Green PCR Master Mix on ABI Prism® 7500 
Real-time PCR System (Applied Biosystems). The threshold cycle (Ct) is defined 
as the PCR cycle number at which the reporter fluorescence achieves the 
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threshold reflecting a statistically significant point above the calculated baseline. 
The Ct of indicated gene was determined and normalized against that of the 
internal control glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  
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Table 2. Primers used for real-time PCR 
Genes Primers 
STAT3 
Forward: 5’-GGCCCCTCGTCATCAAGA 
Reverse: 5’-TTTGACCAGCAACCTGACTTTAGT 
CyclinD1 
Forward: 5’-CTTCCTCTCCAAAATGCCAG 
Reverse: 5’-AGAGATGGAAGGGGGAAAGA 
Survivin 
Forward: 5’-TGCCTGGCAGCCCTTTC 
Reverse: 5’-CCTCCAAGAAGGGCCAGTTC 
MMP-9 
Forward: 5’-TGACAGCGACAAGAAGTG 
Reverse: 5’-CAGTGAAGCGGTACATAGG 
VEGF 
Forward: 5’-TACCTCCACCATGCCAAGTG 
Reverse: 5’-GATGATTCTGCCCTCCTCCTT 
Twist 
Forward: 5’-CGGGAGTCCGCAGTCTTA 
Reverse: 5’-TGAATCTTGCTCAGCTTGTC 
GAPDH 
Forward: 5’-AAGGACTCATGACCACAGTCCAT 
Reverse: 5’-CCATCACGCCACAGTTTCC 
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Q. Co-immunoprecipitation 
(Courtesy of Dr. Fang Wang) 
Co-immunoprecipitation (co-IP) was used to investigate the dimerization 
between HA- and FLAG-tagged STAT3 following indicated treatment. 500 μg of 
fresh cell lysate for each treatment were mixed with 1:100 diluted normal mouse 
IgG in 500 μL of ice-cold lysis buffer used for cell lysate preparation and incubated 
for 1 hour at 4°C. The suspensions were pre-cleared with 150 μL of protein G-
PLUS agarose beads for 1 hour at 4°C. After brief centrifugation at 500 g for 2 
minutes, the supernatants were transferred into new microcentrifuge tubes and 
precipitated with 1:500 diluted monoclonal mouse anti-HA antibody for 3 hours, 
followed with incubation with 50 μL of protein G-PLUS agarose beads overnight at 
4°C. Next day, the supernatants were discarded after centrifugation. The beads 
were washed five times with 1 mL of lysis buffer, followed by SDS-PAGE and 
Western blot analysis. 
 
R. Cellular fractionation 
To determine the STAT3 level in difference cellular fractions following 
treatment, cytosol, soluble nuclear and chromatin-bound proteins were isolated 
followed by SDS-PAGE and Western blot analysis. In brief, after A549 or MDA-
MB-231 cell were exposed to 0.1% DMSO vehicle or inS3-54/A18 for 72 hours, 
cells were harvested, suspended in cytosol extraction buffer (10 mM HEPES·KOH, 
pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1% Triton X-
100, 1 mM DTT, 10 µM leupeptin, 1:1000 diluted protease inhibitor cocktail) and 
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subjected to centrifugation at 4,200 g for 5 minutes to pellet nuclei. The 
supernatants were used as cytosolic fraction after cleaned by a further 
centrifugation step. The pellets were resuspended in soluble nuclear protein 
extraction buffer (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 10 µM leupeptin, 1:1000 
diluted protease inhibitor cocktail) and incubated on ice for 30 minutes, followed 
centrifugation at 5,000 g for 5 minutes. The successive supernatants were used 
as soluble nuclear protein fraction. The insoluble pellets were further resuspended 
in chromatin-bound protein extraction buffer (50 mM Tris·HCl, pH 7.4, 150 mM 
NaCl, 0.5% NP-40, 5 mM EDTA, 50 mM NaF, 1 mM Na3VO4, 1% SDS, 1 mM DTT, 
10 µM leupeptin, 1:1000 diluted protease inhibitor cocktail) and sonicated to 
release proteins from chromatin. Difference cellular fractions were finally subjected 
to SDS-PAGE and Western blot analysis. 
 
S. Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was used to determine the changes 
in binding of STAT3 to the promoter of responsive genes in the absence or 
presence of indicated compounds. After treatment, H1299 cells were treated with 
formaldehyde at a final concentration of 1% for 10 minutes to crosslink protein and 
DNA, followed by harvest and incubation in SDS lysis buffer (50 mM Tris, pH 8.1, 
1% SDS, 10 mM EDTA, 1 mM PMSF, 1:1000 diluted protease inhibitor cocktail) 
on ice for 10 minutes. Cell lysates were sonicated to shear DNA to lengths between 
200 and 1000 basepairs and centrifuged at 13,000 rpm for 10 minutes at 4°C. 
Solubilized chromatin was diluted with ChIP dilution buffer (16.7 mM Tris·HCl, pH 
41 
8.1, 167 mM NaCl, 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, mM PMSF, 
1:1000 diluted protease inhibitor cocktail), precleared with protein A 
agarose/salmon sperm DNA for 30 minutes at 4°C with agitation to reduce 
nonspecific background and incubated with specific STAT3 antibody overnight at 
4°C with rotation. The antibody/protein complex was then collected by incubating 
with protein A agarose/salmon sperm DNA for one hour at 4°C and washed for 5 
minutes with low salt immune complex washing buffer (20 mM Tris·HCl, pH 8.1, 
150 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM EDTA), high salt immune 
complex washing buffer (20 mM Tris·HCl, pH 8.1, 500 mM NaCl, 0.1% SDS, 1% 
Triton X-100, 2 mM EDTA), LiCl immune complex washing buffer  (10 mM Tris·HCl, 
pH 8.1, 250 mM LiCl, 1% NP-40, 1% deoxycholic acid (sodium salt), 1 mM EDTA) 
and TE buffer (10 mM Tris·HCl, pH 8.0, 1 mM EDTA). DNA/protein complex was 
released from antibody with elution buffer (1% SDS, 0.1 M NaHCO3) and the 
crosslink was reversed using 5M NaCl by heating overnight at 65°C. Proteins were 
digested with proteinase K for one hour at 45°C. DNA was recovered by 
phenol/chloroform extraction and cold ethanol precipitation and subjected to PCR 
with primers specific for cyclin D1 or twist promoter, followed by separation on 2.5% 
agarose gel. The sequences of the PCR primers are shown as follows: cyclin D1 
sense primer, 5’-AACTTGCACAGGGGTTGTGT-3’; cyclin D1 antisense primer 5’-
GAGACCACGAGAAGGGGTGACTG-3’; twist sense primer, 5’-
AGTCTCCTCCGACCGCTTCCTG-3’; twist antisense primer 5’-
CTCCGTGCAGGCGGAAAGTTTGG-3’. No-antibody and IgG 
immunoprecipitation was performed as the negative controls accordingly. A portion 
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of the cell lysate was kept to quantitate the amount of DNA present in samples as 
the input control. 
 
T. Determination of in vivo study conditions 
(Pharmacokinetic analyses were performed by Dr. David R. Jones.) 
To determine the optimal conditions used for animal studies, the solubility 
of inS3-54 and its analogues was firstly tested in the commonly-used and 
commercially available formulation. To determine how long the compounds remain 
in solution, indicated compounds were dissolved in various formulations and the 
solubility was observed immediately and 24 hours after allowing to stand at room 
temperature (see Table 6 for summary of formulations and results). 
A pilot toxicity test was performed to determine the tolerance of various 
compounds in mice. Male and female BALB/c or nonobese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice were administrated with increasing 
dosages of indicated compounds by intraperitoneal injection (i.p.) or oral dosing 
(p.o.) with 3 mice per group. Behavior, activity, body weight and death of animals 
were observed and recorded after treatment. To further investigate the 
pharmacokinetic (PK) characteristics of compounds and determine the optimal 
dosing regimens in animal studies, blood sample were also collected in 0, 2, 4, 8, 
16 and 24 hours after drug administration and analyzed for determination of PK 
parameters. 
 
U. Mouse xenograft model of lung cancer 
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(Courtesy of Dr. Karen E. Pollok and In Vivo Therapeutics Core) 
In vivo efficacy of A18 was investigated in a mouse xenograft model of lung 
cancer. 5×106 A549 cells were injected subcutaneously in the flanks of 12 
NOD/SCID mice. When the tumor volume reached about 50.0 mm3, the mice were 
randomized to one vehicle control group and one A18 group (200 mg/Kg/2 days) 
with 6 mice per group. Drug administration was delivered by oral dosing once every 
other day for 4 weeks. Behavior and activity of animals were observed and 
recorded every two days. Tumor volume and body weight were measured twice 
per week. On the 35th day after implant, mice were euthanized and the tumor 
tissues were harvested and weighed. Necropsy was also performed to determine 
the changes in heart, lungs, kidneys, liver and spleen. Differences between both 
groups were analyzed with Student’s t-test. Statistical significance was considered 
at p<0.05. Due to variation in animals, data outliers were rejected by Dixon's Q test 
at 95% confidence. 
 
V. Immunohistochemistry staining 
(Assisted by Histology Core Facilities and Dr. George E. Sandusky) 
Slides containing paraffin-embedded tissue sections were prepared by 
Histology Core Facilities, followed by hematoxylin and eosin (H&E) staining. Slides 
were then read by an experienced pathologist. 
Unstained slides were used to determine the levels of STAT3 and its 
downstream targets in tumor tissues following drug administration. In brief, slides 
were deparaffinized and rehydrated by incubation in xylene overnight followed by 
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incubation in xylene for 30 minutes, in 100% ethanol for 2 minutes two times, in 
95% ethanol for 2 minutes two times and in 75% ethanol for 2 minutes one time. 
Slides were washed in PBST (1×PBS, 0.1% (v/v) Tween-20) for 5 minutes. 
Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide, followed 
by washing five times in PBST for 5 minutes each. For antigen retrieval, slides 
were boiled in target retrieval buffer (10 mM citrate acid, 0.05% (v/v) Tween-20, 
pH 6.0) at 95-100°C for 30 minutes and allowed to cool at room temperature for 5 
minutes, followed by washing with PBST for 5 minutes. Nonspecific binding of 
immunoglobulin was minimized by preincubation in 10% FBS in PBST for 30 
minutes at room temperature. Slides were incubated with primary antibodies 
against STAT3, survivin and VEGF at 4°C overnight according to the 
manufacturer’s instructions. Antigen-antibody complexes were detected using 
biotinylated anti-rabbit or anti-goat secondary antibodies followed by streptavidin-
horseradish-peroxidase substrate. Slides were counterstained with hematoxylin 
for 2 minutes followed by dehydration in 0.25% ammonium hydroxide for 5 minutes, 
75% ethanol for 2 minutes one time, 95% ethanol for 2 minutes two times, 100% 
ethanol for 2 minutes two times and xylene for 10 minutes two times. Coverslips 
were finally mounted using CytosealTM 60 and slides were captured under 
microscopy.  
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III. Experimental Results 
Part I. Development of inS3-54 
A. Identification of a STAT3 inhibitor targeting the DBD of STAT3. 
Disrupting STAT3-DNA interaction with small molecule compounds is an 
emerging therapeutic approach. To identify small molecule compounds that can 
disrupt STAT3-DNA interaction, the crystal structure of STAT3β homodimer bound 
to DNA (PDB code: 1BG1) obtained from Protein Data Bank was used for 
structure-based virtual screening in collaboration with Dr. Jing-Yuan Liu (Figure 
5A). The DNA-binding groove consisting of residues 329~332, 340~346, 406~412 
and 465~468 was chosen as the targeting area for docking. ChemDiv chemical 
database offered approximately 200,000 virtual compounds for molecular docking 
over the DBD of STAT3. Top-scoring compounds that contain phosphate groups 
mimicking phosphates in DNA were eliminated due to their potential poor 
membrane permeability in cells. As STAT1 and STAT3 share extensive sequence 
homology but play opposite roles in tumorigenesis, an ideal STAT3 inhibitor should 
be able to distinguish STAT1 and STAT3 (119). Therefore, the remaining 1,000 
top-scoring compounds were also docked onto the DBD of STAT1 (PDB code: 
1BF5) to rule out the compounds that may bind to STAT1. Subsequently, 100 
potentially specific candidates were selected for in vitro screening (Table 3). 
Of the 100 compounds, 57 available compounds obtained from ChemDiv 
Inc. were further tested for their effects on the transcriptional activity of STAT3 in 
a breast cancer cell line MDA-MB-231 stably transfected with a STAT3-dependent 
luciferase reporter. One of the compounds, #54, showed a remarkable inhibitory 
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effect in a time- and dose-dependent manner (Figure 6A-B; IC50: 13.8 µM). 
Furthermore, the compound was found to exhibit no effect on the reporter driven 
by a p27 promoter lacking STAT3-binding site (Figure 6C). Thus, the inhibition on 
STAT3-dependent luciferase reporter is unlikely due to non-specific effects on the 
expression or activity of the luciferase reporter gene. This compound, 4-[(3E)-3-
[(4-nitrophenyl)-methylidene]-2-oxo-5-phenylpyrrol-1-yl] benzoic acid, was named 
inS3-54 (Figure 5C). A further search of PubChem compound database with high 
throughput screening data on STAT3 inhibitors revealed no identical structure for 
STAT3 inhibition.  
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Table 3. 100 top-scoring compounds obtained from virtual screening 
No. Structure Formula 
M.W. 
(g/mol) 
1 
 
C22H24N2O8 444.43 
2 
 
C22H19N3O6 421.40 
3 
 
C16H10N2O6S2 390.39 
4 
 
C25H19N5O6 485.45 
5 
 
C20H12Br4N6O4 719.96 
48 
6 
 
C18H18N2O4S 358.41 
7 
 
C17H14N2O6S 374.37 
8 
 
C27H21N7O3 491.50 
9 
 
C21H14N2O4 358.35 
10 
 
C22H13N3O7 431.35 
11 
 
C22H16N4O3 384.39 
49 
12 
 
 
C12H11Cl2NO6 336.12 
13 
 
C25H17N5O3S 467.50 
14 
 
C24H26N8O3 474.52 
15 
 
C24H19N7O4 469.45 
16 
 
C28H32N2O2 428.57 
50 
17 
 
C21H12ClNO5S 425.84 
18 
 
C20H16Cl2N2O5 435.26 
19 
 
C23H18BrClN4O6 561.77 
20 
 
C17H13NO4S2 359.42 
21 
 
C20H18N4O4 378.38 
22 
 
C17H11Cl2NO4S2 428.31 
23 
 
C22H18I2N2O6 660.20 
51 
24 
 
C21H18N2O7S 442.44 
25 
 
C22H14N2O7 418.36 
26 
 
C15H15NO6 305.28 
27 
 
C21H25NO5 371.43 
28 
 
C20H11BrN4O3 435.23 
29 
 
C19H13Cl2NO6S 454.28 
30 
 
C26H23N5O4S 501.56 
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31 
 
C18H16N4O3S 368.41 
32 
 
C24H18N4O3 410.42 
33 
 
C15H12N4O5S 360.34 
34 
 
C19H11Cl2N3O4S 448.28 
35 
 
C22H20N2O7 460.44 
36 
 
C21H22N2O7 414.41 
37 
 
C19H19ClN2O5S 422.88 
53 
38 
 
C21H21ClN2O4 400.86 
39 
 
C21H17NO4 347.36 
40 
 
C22H20N2O7S2 488.53 
41 
 
C23H19ClN4O3 424.87 
42 
 
C21H12ClN3O6 437.79 
43 
 
C26H24N2O8 492.48 
54 
44 
 
C18H17Br2N3O5 515.15 
45 
 
C20H18N4O4S 410.45 
46 
 
C24H12IN3O7 581.27 
47 
 
C25H20ClN3O4S 493.96 
48 
 
C28H29N3O4S2 545.68 
49 
 
C17H10N2O7 354.27 
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50 
 
C18H13BrN2O5 417.21 
51 
 
C17H13N3O3S2 317.43 
52 
 
C18H19N3O4S 373.43 
53 
 
C18H11N3O8S2 461.43 
54 
 
C24H16N2O5 412.39 
55 
 
C25H22N4O5S2 522.60 
56 
 
C28H20N2O3S 464.54 
56 
57 
 
C20H14O7S 398.39 
58 
 
C17H14N4O3S 354.38 
59 
 
C22H26N4O4 410.47 
60 
 
C21H15ClN2O7 442.81 
61 
 
C22H17FN4O5S2 500.52 
62 
 
C21H15N3O6 405.36 
57 
63 
 
C21H14BrNO5 440.24 
64 
 
C19H15N3O5 365.34 
65 
 
C28H24N6O2 476.53 
66 
 
C23H20N8O3 456.46 
67 
 
C22H15BrN2O5 467.27 
68 
 
C20H16N6O7S 484.44 
58 
69 
 
C18H17BrN2O6 437.24 
70 
 
C23H17N5O3 411.41 
71 
 
C21H13ClN2O4 392.79 
72 
 
C24H24N2O6 436.46 
73 
 
C22H17N3O3S 403.45 
74 
 
C18H12ClIN2O3 466.66 
75 
 
C20H18N2O5S 398.43 
59 
76 
 
C18H15N3O4S 369.39 
77 
 
C18H17N3O9S 451.41 
78 
 
C27H26N4O4S2 534.65 
79 
 
C19H11N3O9S2 489.44 
80 
 
C19H17NO6 355.34 
81 
 
C21H16N2O7 408.36 
60 
82 
 
C18H20N2O7S 408.43 
83 
 
C22H17N3O6 419.39 
84 
 
C18H13BrN4O5 445.22 
85 
 
C17H13Cl3N4O5S 491.73 
86 
 
C19H16BrNO6 434.24 
87 
 
C17H14N2O6S3 438.50 
88 
 
C17H14N2O5S2 390.43 
61 
89 
 
C17H18N4O4S 374.41 
90 
 
C21H12N2O5 372.33 
91 
 
C20H18ClN3O3 383.83 
92 
 
C16H15BrN2O4 379.21 
93 
 
C17H9Br2NO5 467.07 
94 
 
C23H20BrN3O4 482.33 
62 
95 
 
C17H14ClNO4 331.75 
96 
 
C18H16N2O5S2 404.46 
97 
 
C29H18F2N2O3 480.46 
98 
 
C22H12F3NO6S 475.39 
99 
 
C20H18N2O5S 398.43 
100 
 
C22H12Cl2N2O6 471.25 
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Figure 5. Schematic diagram and identification of inS3-54 by structure-based 
virtual screening. 
(A) The crystal structure of dimeric STAT3β bound to DNA fragment (PDB code: 
1BG1) was used to identify small molecule compounds that can disrupt STAT3-
DNA interaction by structure-based virtual screening. The red box indicates the 
targeting site of one of the STAT3 subunits for molecular docking. (B) Breast 
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cancer cells MDA-MB-231 stably transfected with STAT3-dependent luciferase 
reporter were exposed to 20 µM of compounds for 48 hours followed by 
measurement of luciferase activity. The compound, #54, showed a remarkable 
inhibitory effect on STAT3-dependent luciferase reporter. (C) Chemical structure 
of the compound, #54 (named inS3-54). (N=3; ** p<0.01, by Student’s t-test as 
compared with DMSO vehicle control)  
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Figure 6. Effects of inS3-54 on STAT3 dependent and independent luciferase 
reporter activity. 
(A-B) MDA-MB-231-STAT3 cells harboring a STAT3-dependent luciferase 
reporter construct were treated with increasing concentrations of inS3-54 for 72 
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hours (A) or with 20 µM inS3-54 for indicated time intervals (B), followed by 
luciferase reporter assay. InS3-54 suppressed STAT3-dependent luciferase 
reporter in a dose- and time-dependent manner. (C) H1299 cells were transiently 
transfected with a luciferase reporter construct driven by a p27 promoter lacking 
STAT3-binding sequence. 24 hours after transfection, cells were exposed to 
increasing concentrations of inS3-54 for 48 hours, followed by measurement of 
luciferase reporter activity. InS3-54 had little effect on STAT3-independent 
luciferase reporter.  
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B. InS3-54 selectively inhibits the DNA-binding activity of STAT3 but not that 
of STAT1. 
To determine the selectivity of inS3-54 on STAT subtypes, molecular 
dynamics simulation and generalized GBSA analysis were performed to determine 
the binding free energy of inS3-54 docked in the DBD of these proteins in 
collaboration with Dr. Jing-Yuan Liu as described previously (120). Table 4 shows 
that both STAT molecules have favorable electrostatic (ΔEele) and van der Waals 
(ΔEvdw) interaction energy although the energy is more favorable to STAT3 than to 
STAT1. The energy contribution from solvation (ΔGsolv) reverses these favorable 
energy for both STAT molecules. However, the reversal effect from solvation is 
less for STAT3 than for STAT1. Consequently, the total binding free energy (ΔGbind) 
is much more favorable for STAT3 (-28.4 kcal/mol) than for STAT1 (-17.1 kcal/mol). 
Considering the omitted entropy term, which is always unfavorable, inS3-54 may 
not bind to STAT1 at all or have a very low affinity. Examination of the average 
simulated structure of inS3-54-bound STAT1 or STAT3 agrees with the calculated 
ΔGbind. As shown in Figure 7A, the residues Met331, Val343, Met420, Ile467 and 
Met470 make a great contribution to the binding of STAT3 to inS3-54 via 
hydrophobic interaction. The amino groups of Lys340 and Asn466 stabilize the 
carboxyl group of inS3-54 by favorable electrostatic interaction. However, the 
orientation of inS3-54 docked in STAT1 is distinct from that in STAT3 (Figure 7B-
C). The binding mode in STAT1 likely results in an unfavorable total binding free 
energy. InS3-54 will clash with the residues Pro326 and Thr327 of STAT1 if forcing 
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the compound to adopt the same orientation in STAT1 as in STAT3. Based on 
these analyses, inS3-54 may not bind to STAT1 efficiently. 
EMSA was then used to verify the above findings and to determine the 
inhibitory effect of inS3-54 on the DNA-binding activity of STAT3 and STAT1 using 
[32P]-labeled double strand DNA probe and whole cell lysate extracted from H1299 
cells transiently transfected with constitutively dimerizable FLAG-STAT3 (FLAG-
STAT3c) or STAT1. By substituting cysteine residues for specific amino acids 
within the C-terminal loop in the SH2 domain of the STAT3 molecule, FLAG-
STAT3c spontaneously forms homo-dimers via formation of intermolecular 
disulfide bond, leading to binding to STAT3 responsive element, as described 
previously (121). As shown in Figure 8, the specific binding of STAT3 or STAT1 
to DNA probe was verified by super-shift and competition analyses. InS3-54 
inhibited the DNA-binding activity of STAT3 in a dose-dependent manner whereas 
the binding activity of STAT1 was not affected by inS3-54 up to 300 µM. 
To sum up, inS3-54 selectively blocks the DNA-binding activity of STAT3, 
without affecting STAT1.  
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Table 4. Binding free energy and energy components of inS3-54 
in STAT1 and STAT3 
 ΔEsolute (kcal/mol) ΔGsolv (kcal/mol) 
ΔEtot_ele 
(kcal/mol) 
ΔGbind (kcal/mol) 
 ΔEele ΔEvdw ΔGes ΔGnes 
STAT1 - 139.6±3.4 - 23.1±1.0 149.6±2.4 - 4.0±0.1 10.1±0.4 - 17.1±1.0 
STAT3 - 144.3±4.4 - 27.5±0.9 148.0±2.8 - 4.6±0.1   3.6±0.8 - 28.4±0.9 
Data are presented as mean±SEM. 
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Figure 7. Molecular dynamics simulation of inS3-54 binding to STAT3 or 
STAT1. 
(A) Average complex structure of inS3-54 in the DBD of STAT3 from molecular 
dynamics simulation. InS3-54 binds to the residues Met331, Val343, Met420, 
Ile467 and Met470 via hydrophobic interaction and the residues Lys340 and 
Asn466 via electrostatic interaction. InS3-54 is shown in ball-and-stick 
representation. (B-C) Molecular surface of STAT3 (B) and STAT1 (C) bound to 
inS3-54 from molecular dynamics simulation with orientation shown in gold for 
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STAT3 and pink for STAT1. The molecular surface is colored by atom types with 
gray for carbon, blue for nitrogen, red for oxygen and yellow for sulfur.  
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Figure 8. InS3-54 inhibits the DNA-binding activity of STAT3 but not that of 
STAT1. 
The DNA-binding activity of STAT3 (A) and STAT1 (B) was assessed by EMSA 
following inS3-54 treatment. The whole cell lysates extracted from H1299 cells 
73 
transiently transfected with constitutively dimerizable FLAG-STAT3 or STAT1 
were pre-incubated with increasing concentrations of inS3-54 for 30 minutes prior 
to addition of [32P]-labeled double strand DNA probe that contains a STAT3 DNA-
binding site for 20 minutes at room temperature. The reaction mixtures were then 
resolved on 6% non-denaturing polyacrylamide gel and detected by 
autoradiography. InS3-54 inhibited the binding of STAT3 to radiolabeled probe but 
not that of STAT1.  
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C. Binding of inS3-54 to STAT3. 
To further verify that inS3-54 can indeed bind to STAT3, inS3-54 containing 
a carboxyl group was conjugated to EAH-Sepharose 4B, followed by pull down 
assay with lysate of H1299 cells transfected with FLAG-STAT3c (Figure 9A). 
Figure 9B-D shows that inS3-54-conjugated beads successfully pulled down 
STAT3 whereas the vehicle control beads or the irrelevant compound (C5)-
conjugated beads did not. However, multiple bands were detected by gel silver 
staining, suggesting that other proteins may interact with inS3-54. Furthermore, 
pretreatment of the cell lysate with excess free inS3-54 abrogated the interaction 
between STAT3 and inS3-54-conjugated beads (Figure 9E). Importantly, the 
commercially purified STAT3 protein was also pulled down by inS3-54-conjugated 
beads (Figure 9F). Thus, inS3-54 can bind to STAT3 directly although the result 
of silver staining suggests that potential off-targets of inS3-54 may exist. 
Recently, alkylation of cysteine 468 that is located in the DNA-binding 
domain of STAT3 has been found to define a novel site for therapeutic 
development (93). However, the alkylating agent reported can also interact with 
other surface-exposed cysteine residues by alkylating the thiol group of cysteine, 
indicating low specificity on STAT3. Although the molecular dynamics simulation 
shows that inS3-54 interacts with STAT3 via hydrophobic and electrostatic 
interaction, considering the similar property of their chemical structures, we tested 
whether or not inS3-54 might act as an alkylating agent by using glutathione as a 
substrate. After A549 and MDA-MB-231 cells were exposed to 20 µM inS3-54 for 
48 hours, a luminescence-based glutathione assay showed that inS3-54 did not 
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affect the level of glutathione in cells (Figure 10). In contrast, the positive control 
IAA, which binds covalently with the thiol group of cysteine, significantly reduced 
the level of glutathione (Figure 10). Thus, inS3-54 likely does not alkylate STAT3 
via alkylation of the thiol group of cysteine residues and the interaction between 
inS3-54 and STAT3 is not due to alkylation of cysteine residues on STAT3 under 
which condition the compound has inhibitory effect on STAT3 signaling.  
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Figure 9. (Continued)  
77 
 
Figure 9. Binding of inS3-54 to STAT3. 
(A) H1299 cells were transiently transfected by vector control (Vec) or 
constitutively dimerizable FLAG-STAT3c (ST3), followed by SDS-PAGE and 
Western blot analysis. (B-C) Total lysates obtained from FLAG-STAT3c-
transfected H1299 cells were incubated with EAH-Sepharose 4B-conjugated with 
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vehicle control (VC), inS3-54 (inS3) or irrelevant compound (C5). Proteins bound 
to beads were subjected to SDS-PAGE followed by Western blot analysis probed 
with specific anti-FLAG antibody or gel silver staining. Unbound flow-through 
samples were used as the input control. (D) Proteins bound to beads were eluted 
from beads with excess free inS3-54. (E) Binding of STAT3 to inS3-54-conjugated 
EAH-Sepharose 4B beads was competed by pretreatment of excess free DMSO 
vehicle control (VC), inS3-54 (inS3) or irrelevant compound (C5). (F) Purified 
STAT3 protein with His-tag was subjected to pull down assay following the same 
procedure. InS3-54 can directly bind to STAT3.  
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Figure 10. InS3-54 does not alkylate cysteine using glutathione as a 
substrate. 
After A549 and MDA-MB-231 cells were exposed to DMSO (0.1%) or 20 µM inS3-
54 for 48 hours or 15 mM IAA for 30 minutes, the level of glutathione was assessed 
by GSH-GloTM glutathione assay following the manufacturer’s instructions. InS3-
54 had no significant effect on the glutathione level in both cell lines under which 
condition the compound has inhibitory effect on STAT3 signaling. IAA was used 
as a positive control. (N=3; *** p<0.001, by Student’s t-test as compared with 
DMSO vehicle control)  
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D. InS3-54 does not inhibit STAT3 dimerization. 
The SH2 domain of STAT3 has previously been shown to be susceptible 
for binding with inhibitors. To rule out the possibility that inS3-54 has off-target 
effect on the SH2 domain without targeting the DBD of STAT3, STAT3 dimerization 
was investigated by transiently transfecting FLAG-STAT3c into H1299 cells 
followed by the treatment with 0.1% DMSO vehicle control, 20 μM inS3-54 or a 
previously reported STAT3 inhibitor S3I-201 that binds to the SH2 domain (74). 
Figure 11A shows that STAT3c spontaneously formed both dimeric and 
monomeric forms of STAT3 after transiently transfected to H1299 cells. Treatment 
with inS3-54 did not affect the production of dimeric STAT3c whereas the positive 
control, S3I-201, inhibited its dimerization (Figure 11B). To further confirm this 
observation, a co-IP analysis of HA- and FLAG-tagged STAT3 was performed. 
Figure 11C shows that HA- and FLAG-tagged STAT3 can be co-expressed and 
co-immunoprecipitated successfully in H1299 cells. The dimerization between HA- 
and FLAG-tagged STAT3 was not affected following inS3-54 treatment while S3I-
201 abrogated STAT3 dimerization (Figure 11D). Although the decline of STAT3 
dimerization is less distinct as that found using STAT3c (Figure 11B), it is possibly 
due to the potential re-association of STAT3 molecules during the process of co-
IP lacking S3I-201. The results indicate that inS3-54 does not inhibit STAT3 
dimerization and likely does not bind to the SH2 domain of STAT3.  
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Figure 11. (Continued)  
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Figure 11. InS3-54 does not affect STAT3 dimerization. 
(A) H1299 cells were transiently transfected with vector control (Vec) or 
constitutively dimerizable FLAG-STAT3c (ST3) followed by Western blot analysis. 
β-actin was used as a loading control. Dimeric STAT3 was spontaneously formed. 
(B) FLAG-STAT3c-transfected H1299 cells were treated with DMSO (0.1%), 20 
µM inS3-54 or 20 µM S3I-201 followed by Western blot analysis of STAT3 status. 
InS3-54 did not affect STAT3 dimerization. S3-201 was used as a positive control.  
(C) Lysates extracted from H1299 cells transfected with HA-tagged, FLAG-tagged 
STAT3 or both were subjected to co-IP and Western blot analyses. (D) H1299 cells 
co-expressed with HA- and FLAG-tagged STAT3 were exposed to DMSO (0.1%), 
20 µM inS3-54 or 20 µM S3I-201 followed by co-IP with anti-HA antibody and 
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Western blot analysis with anti-FLAG antibody. InS3-54 did not affect the 
dimerization between HA- and FLAG-tagged STAT3. S3-201 was used a positive 
control.  
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E. InS3-54 favorably inhibits cancer cell survival possibly by inducing 
apoptosis. 
To determine whether inS3-54 inhibits the growth and survival of cancer 
cells harboring constitutively activated STAT3, the viability of two lung cancer cell 
lines (A549 and H1299) and two breast cancer cell lines (MDA-MB-231 and MDA-
MB-468) as well as a normal lung fibroblast (IMR90) and a mammary epithelial cell 
line (MCF10A1) was evaluated following inS3-54 treatment. Of four cancer cell 
lines, A549 and H1299 NSCLC cell lines represent a type of lung cancer which is 
relatively insensitive to chemotherapy, compared to small cell lung carcinoma. And 
MDA-MB-231 and MDA-MB-468 cell refer to triple-negative breast cancer cell lines 
which lack effective treatment targets. All these cancer cell lines have been 
demonstrated to harbor constitutive STAT3 signaling and thereby used in many 
studies to identify STAT3 inhibitors (72-81). However, the human fibroblast strain 
IMR-90 was derived from the lungs of a 16-week female fetus and induced to 
achieve senescence bypass (122). MCF10A1 is a subclone of a spontaneously 
immortalized non-tumorigenic human breast epithelial cell line established from 
long term culture of a breast subcutaneous mastectomy (123). Both kinds of cell 
lines served as the control cell lines due to their low STAT3 background level. As 
shown in Figure 12A, the cancer cells showed persistent STAT3 activity as 
assessed by the phosphorylation of STAT3 at Tyr705, compared to the non- non-
tumorigenic cells. The cancer cells appeared to be more sensitive to inS3-54 with 
lower IC50 than the normal cells (Figure 12B-C), suggesting the existence of a 
therapeutic window for inS3-54. 
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To determine whether apoptosis contributes to inS3-54 induced loss of 
tumor cell viability, the exponentially growing lung and breast cancer cells (A549 
and MDA-MB-231) were treated with DMSO control (0.1%) or inS3-54 (5, 10 and 
20 µM) for 72 hours and analyzed by enzyme-linked immunosorbent assay (ELISA) 
which determines DNA fragmentation and histone release from the nucleus during 
the apoptosis process. As shown in Figure 13, inS3-54 induced apoptosis in both 
A549 and MDA-MB-231 cells in a dose-dependent manner.  
86 
 
Figure 12. InS3-54 favorably inhibits cancer cell proliferation. 
(A) The total and phosphorylated STAT3 in the indicated cell lines were assessed 
by Western blot analysis. β-actin was used as a loading control. All cancer cell 
lines showed a higher level of phospho-STAT3 than normal cells. (B-C) Six cell 
lines were subjected to SRB assay after treatment with increasing concentrations 
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of inS3-54 for 72 hours. Cancer cells were more sensitive to inS3-54 than normal 
cells.  
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Figure 13. InS3-54 induces apoptosis. 
Exponentially growing A549 (A) and MDA-MB-231 (B) cells were treated with 
DMSO (0.1%), 5, 10 or 20 µM inS3-54 for 72 hours followed by determination of 
apoptosis using ELISA. InS3-54 induced apoptosis in both cell lines. (N=3; * 
p<0.05, ** p<0.01, by Student’s t-test as compared with DMSO vehicle control)  
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F. InS3-54 inhibits cancer cell migration and invasion. 
STAT3 plays an important role in promoting cell migration and invasion by 
regulating the expression of the downstream genes such as MMP-1, 2, 7, 9, 10, 
twist and VEGF which favor these processes (52, 53). Firstly, the inhibitory effect 
of inS3-54 on cell migration was determined using wound filling assay which is one 
of the earliest developed models to study directional cell migration in vitro. By 
creating a “wound” in the cell monolayer, the cells at the edge became motile to 
close the gap. This method is particularly suitable to assess the effects of any 
treatment on cell migration. Figure 14 shows that inS3-54 inhibited migration of 
both A549 and MDA-MB-231 cells in a dose- and time- dependent manner. At 24 
hours, 68% and 95% of wounds were filled in the DMSO control-treated A549 and 
MDA-MB-231 cells, respectively. However, only 54% and 77% of the wounds were 
filled in A549 and MDA-MB-231 cells respectively following the treatment with10 
µM inS3-54. The wound filling was further reduced to 27% and 29% in the cells 
treated with 20 µM inS3-54. 
Additionally, metastatic tumor cells must be able to break away from the 
primary tissue, digest the basement membrane as well as invade nearby vessels. 
To determine the effects of inS3-54 on cell metastatic potential, we used Matrigel 
invasion assay which provides a reconstituted basement membrane in vitro and 
thereby allows to assess the invasive property of cells. Under the attraction of 
serum which is essential for cell growth, invasive cells detached from Matrigel 
matrix and invaded through the pores of the membrane. As shown in Figure 15, 
both A549 and MDA-MB-231 cells exhibited significantly decreased invasion 
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through Matrigel-coated filter in the presence of 10 or 20 µM inS3-54 as compared 
with the vehicle control-treated cells. After 6-hour treatment of 10 and 20 µM inS3-
54, the invasion was reduced to 67% and 49% in A549 cells and to 52% and 24% 
in MDA-MB-231 cells, respectively. At 24 hours, the invasion was reduced to 71% 
and 24% in A549 and MDA-MB-231 cells exposed to 10 µM inS3-54, respectively. 
At 20 µM, the invasion of A549 and MDA-MB-231 cells was further reduced to 33% 
and 5% compared to the vehicle control, respectively. 
Since inhibition of cell proliferation may contribute to the positive outcome 
in the above cell migration and cell invasion models, 100% confluent cells and 
short treatment time were applied to the above assays. To further eliminate this 
possibility, cell proliferation and apoptosis were analyzed under the same condition 
as wound filling and Matrigel invasion assays with confluent cultures. As shown in 
Figure 16, treatment with 20 µM inS3-54 for 24 hours had no significant effect on 
proliferation and apoptosis of confluent A549 cells although 20 µM inS3-54 
decreased proliferation and induced apoptosis of MDA-MB-231 cells compared to 
the control group. However, 10 µM inS3-54 did not significantly affect proliferation 
or apoptosis of MDA-MB-231 cells, under which condition it significantly reduced 
the migration and invasion activity of MDA-MB-231 cells (Figure 14-15). No 
apoptosis was also observed when cells were exposed to 20 µM inS3-54 for 6 
hours in both cell lines. Furthermore, MDA-MB-231 cells were observed to remain 
round in morphology at 6 hours. Due to similar phenomena found in both DMSO 
control and A18-treated cells, it is probably resulted from the specific cell line that 
costs more time to spread well after invading. Based on the above analyses, inS3-
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54 was found to inhibit cancer cell migration and invasion which is unlikely due to 
its effects on apoptosis and cell proliferation.  
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Figure 14. (Continued)  
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Figure 14. InS3-54 inhibits cancer cell migration. 
Cell migration was assessed by wound filling assay in A549 (A-B) and MDA-MB-
231 (C-D) cells following treatment with DMSO (0.1%), 10 or 20 µM inS3-54 for 24 
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hours. Panel B and D show the quantification analysis of wound filling assay from 
at least three independent experiments. InS3-54 suppressed cell migration in both 
cell lines.  
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Figure 15. (Continued)  
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Figure 15. InS3-54 inhibits cancer cell invasion.  
Cell invasion was determined in A549 (A-B) and MDA-MB-231 cells (C-D) in 
presence of DMSO (0.1%), 10 or 20 µM inS3-54 for 6 or 24 hours using Matrigel 
invasion assay with 10% FBS in the bottom chamber as a chemoattractant. Panel 
B and D show the quantification of invasion from measurement of 10 random views 
at each of three independent experiments. InS3-54 repressed cancer invasion in 
both cell lines. (N=3; * p<0.05, ** p<0.01, *** p<0.001, by Student’s t-test as 
compared with DMSO vehicle control)  
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Figure 16. (Continued)  
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Figure 16. Effects of inS3-54 on cell growth and apoptosis of confluent cells. 
100% confluent A549 (A and C) and MDA-MB-231 (B and D) cells were treated 
with DMSO (0.1%), 10 or 20 µM inS3-54 for 6 or 24 hours followed by 
determination of change in cell number for proliferation (A-B) or ELISA for 
apoptosis (C-D). InS3-54 had no effect on confluent A549 cells but MDA-MB-231 
cells were affected at 24 hours. (N=3; * p<0.05, ** p<0.01, by Student’s t-test as 
compared with DMSO vehicle control) 
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G. InS3-54 inhibits the expression of STAT3 downstream target genes and 
STAT3 binding to its endogenous target sequences. 
To investigate the molecular mechanisms for inhibition of cell proliferation, 
migration and invasion by inS3-54, the expression of the known STAT3 target 
genes was examined in A549 and MDA-MB-231 cells following inS3-54 treatment. 
Immunoblotting analysis of whole-cell lysates showed obvious reduction in 
expression of cyclin D1, survivin, MMP-2, MMP-9, twist and VEGF in response to 
inS3-54 treatment (Figure 17A-C), indicating that inS3-54 suppresses the 
expression of cell cycle, anti-apoptotic and metastatic regulatory genes in 
malignant cells. This observation was also confirmed by real-time PCR analysis of 
mRNAs in both cancer cell lines (Figure 17D-E). It is noteworthy that inS3-54 
dramatic reduced the protein levels of STAT3 downstream targets in a dose-
dependent manner whereas the changes on the mRNA level were not remarkable. 
There are many factors that may affect the correlation between protein and mRNA 
levels. For example, the half-life of different proteins varies from minutes to days 
while the degradation rate of mRNA falls within a tight range. Other factors include 
the lower rate of mRNA transcription compared to protein translation in mammalian 
cells. It is possible that the changes on gene expression level are not reflected at 
the protein level. Moreover, it is unknown whether inS3-54 has off-target effects 
that may impact on protein synthesis or protein stability. Importantly, this 
experiment was intended to detect the changes of STAT3 downstream expression 
and our data indicate that inS3-54 can repress the expression of STAT3 
downstream targets on the protein and mRNA levels. 
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Additionally, inS3-54 treatments had no effect on the total STAT3 or its 
phosphorylation at Tyr705 (Figure 17A), suggesting that inS3-54 may not affect 
the expression or activation of STAT3. In addition to constitutively activated STAT3, 
we also determined whether or not inS3-54 is capable of inhibiting cytokine-
induced STAT3 phosphorylation as the level of serum IL-6 has been shown to be 
elevated in cancer patients and associate with constitutive activation of STAT3 
(124, 125). Following serum starvation, A549 cells were pre-treated with 0.1% 
DMSO control or 20 µM inS3-54 followed by IL-6 stimulation, phospho-STAT3 
(Tyr705) expression was observed to be induced to the same level (Figure 18). 
One of the STAT3 target genes, survivin, was also elevated by 17 folds following 
IL-6 stimulation in the control cells. However, inS3-54 treatment abrogated the IL-
6 induced survivin expression by 46% (Figure 18). These results indicate that 
inS3-54, which is designed to target the STAT3 DBD, likely does not affect the 
expression or activation of constitutive STAT3 or IL-6-induced STAT3 but 
represses the expression of STAT3 target genes. 
Taking into account the EMSA data showing that inS3-54 inhibits the DNA-
binding activity of STAT3 in vitro, the inS3-54 inhibition of STAT3 target gene 
expression may be due to blocking the binding of STAT3 to DNA in cells. To test 
this possibility, A549 and MDA-MB-231 cells were treated with 0.1% DMSO, 10 or 
20 µM inS3-54 followed by fractionation of cytosol, soluble nuclear fraction and 
chromatin-bound proteins. The STAT3 level in these fractions was investigated by 
Western blot analysis. As shown in Figure 19, the chromatin-bound STAT3 
decreased while the STAT3 level in soluble nuclear fraction increased with the 
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increasing concentration of inS3-54, suggesting that inS3-54 effectively inhibits the 
binding of STAT3 to its endogenous target sequences on genomic DNA in situ. 
Two of the downstream genes, cyclin D1 and twist, were also selected for further 
verification of inhibition of inS3-54 on the DNA binding of STAT3 using ChIP assay. 
InS3-54 was found to block the binding of STAT3 to the promoter regions of cyclin 
D1 and twist (Figure 20). Taken together with the results shown above, we 
conclude that inS3-54 inhibits STAT3 activity in binding to endogenous promoters 
on genomic DNA, resulting in reduced transcription of its downstream target genes.  
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Figure 17. (Continued)  
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Figure 17. InS3-54 inhibits the expression of STAT3 downstream target 
genes. 
(A-C) A549 and MDA-MB-231 cells were exposed to DMSO (0.1%), 10 or 20 µM 
inS3-54 followed by lysate preparation and Western blot analysis with antibodies 
indicated. β-actin was used as a loading control. Panel B and C shows the 
quantitative data measured by the density of Western blot bands and normalized 
against the β-actin internal control. Results indicate that inS3-54 inhibited protein 
expression of STAT3 downstream targets in both cells lines. (N=3; * p<0.05, ** 
p<0.01, by Student’s t-test as compared with DMSO vehicle control) (D-E) A549 
(D) and MDA-MB-231 (E) cells were exposed to 0.1% DMSO or 20 µM inS3-54 
104 
followed by extracting total RNA and real-time PCR analysis of selected genes. 
GAPDH was used an internal control. InS3-54 inhibited mRNA level of STAT3 
downstream targets in both cells lines. (N=4; * p<0.05, ** p<0.01, *** p<0.001, by 
Student’s t-test as compared with DMSO vehicle control)  
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Figure 18. InS3-54 does not affect IL-6 induced STAT3 phosphorylation. 
A549 cells were cultured in serum-free medium for 2 days and then pre-treated 
with 20 µM inS3-54 for 12 hours followed by addition of 25 ng/mL of IL-6 for 30 
minutes. After treatment, the expression levels of phospho-STAT3, STAT3 and 
survivin were examined by Western blot analysis. IL-6 induced phosphorylation of 
STAT3 was not affected by inS3-54 treatment whereas IL-6 stimulated survivin 
was still down-regulated by 46%.  
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Figure 19. InS3-54 inhibits STAT3 binding to chromatin. 
A549 and MDA-MB-231 cells were treated with 0.1% DMSO, 10 or 20 µM inS3-54 
for 72 hours followed by fractionation of cytosol, soluble nuclear fraction, and 
chromatin-bound proteins and Western blot analysis of STAT3 in these fractions. 
α-Tubulin, histone 2A/3 and β-actin were used as loading controls for various 
protein fractions. InS3-54 blocked the binding of STAT3 to genomic DNA.  
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Figure 20. InS3-54 inhibits the binding of STAT3 to the promoter regions of 
responsive genes. 
H1299 cells were treated with 0.1% DMSO or 20 µM inS3-54 for 24 hours followed 
by ChIP assay and agarose gel electrophoresis. No antibody and IgG were used 
as background negative controls. The binding of STAT3 to cyclin D1 or twist 
promoter was abrogated following inS3-54 treatment.  
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Part II. Development of inS3-54 analogues 
A. Analogues of inS3-54 targeting the DBD of STAT3 are developed. 
To investigate the structure-activity relationship (SAR) of inS3-54, 79 
available analogues of inS3-54 were obtained by searching the Chemdiv database 
with a criterion of 80% structural similarity using the Chemfinder module in 
Chemoffice 8.0 (Table 5). These compounds were then assessed by a STAT3-
dependent luciferase reporter assay in MDA-MB-231-STAT3 cells as we identified 
inS3-54 previously. Three compounds (named A18, A26 and A69) were more 
active in inhibiting STAT3-dependent luciferase activity as compared with the 
parental compound inS3-54 while A18 and A69 showed statistically significant 
difference (p<0.05) (Figure 21A). Further analysis confirmed that A18, A26 and 
A69 suppressed STAT3 signaling in a dose- and time-dependent manner with IC50 
of 8.8~10.6 µM (Figure 21B-C and Table 5) whereas the three analogues did not 
exert any effect on the reporter expression driven by a p27 promoter containing no 
STAT3-binding site as previously described (Figure 21D), suggesting their specific 
effects on STAT3-dependent luciferase reporter. Inhibition of the reporter 
expression by inS3-54 analogues is thus unlikely due to its non-specific effect on 
the expression or activity of the reporter gene. Interestingly, A18, A26 and A69 had 
comparable IC50 whereas inS3-54 and A69 cost shorter time to achieve 50% 
inhibition on STAT3-dependent luciferase reporter than A18 and A26, probably 
due to the higher polarity. Furthermore, 10 analogues of A79 (A80~A89) were 
synthesized manually in collaboration with Dr. Zhong-Yin Zhang and then tested 
for their activity in inhibiting STAT3-dependent luciferase reporter activity. As 
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shown in Figure 21A and Table 5, none of these 10 derivatives had any inhibitory 
activity. Therefore, the three analogues of inS3-54 (A18, A26 and A69) from 
ChemDiv library were selected for more tests to investigate their effects on 
inhibition of constitute STAT3 signaling. 
An in vitro colony formation assay using wild-type and conditional STAT3 
knock-out bone marrow cells then provide a tool to determine the potential 
specificity of the compounds on STAT3 protein. Conditional knock-out of STAT3 
has been demonstrated to reduce about 50% of colony formation potential in 
granulocyte macrophage (CFU-GM), erythroid (BFU-E) and multi-potential (CFU-
CEMM) hematopoietic progenitor cells compared to wile-type cells as described 
previously (116, 117). It is assumed that the STAT3-specific compounds suppress 
colony formation of STAT3+/+ cells, but do not further affect the colony formation 
potentials of progenitor cells from the STAT3-/- mice. Unfortunately, inS3-54 
inhibited colony formation of CFU-GM, BFU-E and CFU-GEMM from both control 
mice (C57BL/B; STAT3+/+) and STAT3-/- mice after these progenitor cells isolated 
from bone marrow were exposed to inS3-54, suggesting a low specificity of inS3-
54 for STAT3 (Figure 22). However, the three active analogues (A18, A26 and 
A69) affected colony formation of progenitor cells from only STAT3+/+ but not 
STAT3-/- mice (Figure 22), indicating that A18, A26 and A69 are likely specific to 
STAT3 whereas inS3-54 may also work on other targets in addition to STAT3 that 
are important for colony formation of hematopoietic progenitor cells. 
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Taken together, three active analogues of inS3-54 (A18, A26 and A69) 
show remarkable activity in inhibiting STAT3-dependent luciferase activity as well 
as are more specific to STAT3 signaling than their parental compound, inS3-54.  
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Table 5. Chemical properties of inS3-54 and its analogues 
 
Core Structure 
Name R1 R2 Formula 
M.W. 
(g/mol) 
inS3-
54 
  
C24H16N2O5 412.41 
A1  
 
C18H16N2O 276.33 
A2 
 
 
C28H17Cl2NO4 502.34 
A3 
 
 
C28H18ClN2O4 517.36 
A4 
 
 
C28H20N2O4 448.47 
A5 
 
 
C29H22N2O4 462.50 
A6 
 
 
C27H17ClN2O4 468.89 
A7 
 
 
C28H20N2O5 464.47 
A8 
  
C29H20N2O5 476.48 
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A9 
 
 
C28H20N2O4 448.47 
A10 
  
C27H17ClN2O4 468.88 
A11 
 
 
C27H17FN2O4 452.43 
A12 
 
 
C28H20N2O5 464.47 
A13 
  
C27H17N3O6 479.44 
A14 
  
C27H17ClN2O4 468.89 
A15 
  
C23H16ClNO 357.83 
A16 
  
C23H15Cl2NO 392.28 
A17 
  
C24H18ClNO2 387.86 
A18 
  
C23H16ClNO2 373.83 
A19 
 
 
C25H18ClNO3 415.87 
A20 
  
C29H20ClNO 433.93 
A21 
  
C27H24ClNO 413.94 
A22 
  
C23H15ClFNO 375.82 
A23 
  
C25H18ClNO3 415.87 
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A24 
 
 
C23H15ClN2O3 402.83 
A25 
 
 
C24H17ClN2O3 416.86 
A26 
 
 
C25H19ClN2O2 414.88 
A27 
 
 
C23H15Cl2NO 392.28 
A28 
 
 
C29H21ClN2O 448.94 
A29 
  
C25H20N2O3 396.44 
A30 
  
C25H20N2O3 396.44 
A31 
 
 
C23H15ClN2O3 402.83 
A32 
  
C24H18N2O4 398.41 
A33 
 
 
C24H18N2O4 398.41 
A34 
 
 
C25H18N2O5 426.42 
A35 
 
 
C29H20N2O3 444.48 
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A36 
 
 
C24H18N2O3 382.41 
A37 
 
 
C25H20N2O3 396.44 
A38 
  
C23H15ClN2O3 402.83 
A39 
  
C23H14Cl2N2O3 437.27 
A40 
 
 
C23H15FN2O3 386.38 
A41 
  
C24H18N2O4 398.41 
A42 
  
C23H16N2O4 384.38 
A43 
  
C25H18N2O5 426.42 
A44 
 
 
C23H15N3O5 413.38 
A45 
 
 
C27H25N3O3 439.51 
A46 
  
C27H18N2O3 418.44 
A47 
  
C25H19N3O4 425.44 
A48 
  
C23H14Cl2N2O3 437.27 
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A49 
 
 
C29H21N3O3 459.50 
A50 
 
 
C26H21NO4 411.45 
A51 
 
 
C28H21NO2 403.47 
A52 
 
 
C24H17Cl2NO2 422.30 
A53 
  
C24H18FNO2 371.40 
A54 
  
C26H21NO4 411.45 
A55 
 
 
C30H33N2O4S 506.57 
A56 
 
 
C28H21NO2 403.47 
A57 
 
 
C24H18ClNO2 387.86 
A58 
 
 
C24H17ClN2O2 422.30 
A59 
 
 
C27H18ClNO 407.89 
A60 
 
 
C26H22N2O3 410.46 
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A61 
 
 
C28H17Cl2NO4 502.34 
A62 
 
 
C27H18N2O4 434.44 
A63 
  
C28H18N2O7 494.45 
A64 
 
 
C28H20N2O4 448.47 
A65 
 
 
C25H18ClNO2 399.87 
A66 
 
 
C25H17Cl2NO3 450.31 
A67 
  
C27H15ClN2O 428.95 
A68 
 
 
C23H16N2O3 368.38 
A69 
 
 
C23H16N2O4 384.38 
A70 
 
 
C24H16N2O6 428.39 
A71 
 
 
C25H18N2O4 410.42 
A72 
  
C24H19NO3 369.41 
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A73 
 
 
C24H19NO3 369.41 
A74 
  
C26H24N2O2 396.48 
A75 
  
C26H20ClNO3 429.89 
A76 
 
 
C24H18ClNO2 387.86 
A77 
 
 
C23H15Cl2NO 392.28 
A78 
 
 
C25H21N3O3 411.45 
A79 
 
C23H22N2O6 422.43 
 
Core Structure 
A80 
  
C19H15ClBrNO4 436.68 
A81 
  
C25H20ClNO4 433.88 
A82 
 
 
C20H16ClNO7 417.80 
A83 
 
 
C20H16ClNO7 417.80 
A84 
  
C20H18ClNO4 371.81 
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A85 
 
 
C19H16ClNO7S 437.85 
A86 
 
 
C21H20ClNO5 401.84 
A87 
  
C27H25NO5 443.49 
A88 
 
 
C26H20ClBrN2O6 571.80 
A89 
 
C21H18ClNO6 415.82 
  
  
 
Table 6. Summary of inS3-54 and its active analogues 
Compounds 
Inhibition of STAT3- 
dependent luciferase activity 
Inhibition of cell survival 
IC50 (µM) 
IC50 (µM) Half Time (hrs) 
Lung Breast 
IMR90 A549 H1299 MCF10A1 MB-231 MB-468 
inS3-54 13.8±0.4 29.2±4.7 10.0±2.3 5.4±0.6* 4.7±1.7* 12.0±1.0  4.8±0.5**  3.2±0.3** 
A18    10.6±0.5## 38.5±6.6 10.5±0.2   4.0±0.7***   4.7±0.8***   7.0±2.1 3.2±0.6* 3.5±0.6 
A26    8.8±1.8#  49.9±9.9#   4.0±0.3 2.6±0.4* 3.4±0.2*   9.2±1.8  3.2±0.4***  1.8±0.2*** 
A69 12.6±2.2   12.7±0.6##   9.2±0.8  5.3±1.0**  5.6±1.4** 10.3±0.8  5.0±0.3**  2.6±0.2** 
Data are presented as mean±SD. # p<0.05, ## p<0.01, by Student’s t-test as compared with inS3-54. * p<0.05, ** p<0.01, 
*** p<0.01, by Student’s t-test as compared with respective non-cancer cell lines. 
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Figure 21. Identification of inS3-54 analogues. 
(A) Effects of inS3-54 analogues on STAT3-driven luciferase expression. MDA-
MB-231 cells stably transfected with STAT3-dependent luciferase reporter were 
122 
treated with vehicle control (0.1% DMSO), 20 μM of inS3-54 or its analogues (A1-
A89), followed by measurement of luciferase activity. A18 and A69 are significantly 
more active than inSTAT3-54. Red line indicates 100% as defined by DMSO 
vehicle control. Green line indicates the effect of inS3-54 on STAT3-dependent 
luciferase reporter. (B-C) Effects of three active inS3-54 analogues on STAT3-
dependent luciferase reporter expression. MDA-MB-231-STAT3 cells were 
exposed to increasing concentrations of inS3-54 or its analogues for 72 hours (B) 
or exposed to 20 µM inS3-54 or its analogues for various time intervals (C) followed 
by luciferase reporter assay. Three analogues inhibited STAT3-dependent 
luciferase reporter in a dose- and time-dependent manner. (D) Effects of three 
active inS3-54 analogues on STAT3-independent luciferase reporter expression. 
H1299 cells were transiently transfected with a luciferase reporter construct driven 
by a p27 promoter lacking STAT3-binding sequence followed by treatment with 
increasing concentrations of inS3-54 or its analogues for 48 hours. (N=3; * p<0.05, 
** p<0.01, *** p<0.001, by Student’s t-test as compared with DMSO vehicle control; 
# p<0.05, ### p<0.001, by Student’s t-test as compared with inS3-54)  
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Figure 22. Effects of inS3-54 and its active analogues on colony formation of 
hematopoietic progenitor cells. 
Hematopoietic progenitor cells isolated from STAT3+/+ (A) and STAT3-/- (B) mice 
were cultured in the presence of vehicle control (0.1% DMSO), 20 μM inS3-54 or 
its analogues (A18, A26 and A69) followed by counting of colonies formed. Three 
analogues reduced colony formation of CFU-GM, BFU-E, and CFU-GEMM from 
only STAT3+/+ but not STAT3-/- mice.  
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B. InS3-54 analogues selectively inhibit the DNA-binding activity of STAT3 
other than that of STAT1. 
Previous studies have revealed that inS3-54 selectively blocks the DNA-
binding activity of STAT3, without affecting STAT1. The same EMSA was also 
performed to evaluate three active analogues. As shown in Figure 23, the specific 
binding of DNA probe to STAT3 or STAT1 was demonstrated using super-shift and 
competition analyses. A18, A26 and A69 all inhibited the DNA- binding activity of 
STAT3 in a dose-dependent manner whereas none of them affected the specific 
binding of DNA probe to STAT1. Overall, inS3-54 analogues selectively block the 
DNA-binding activity of STAT3 but not that of STAT1.  
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Figure 23. (Continued)  
126 
 
Figure 23. (Continued)  
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Figure 23. (Legend on next page)  
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Figure 23. InS3-54 analogues inhibits the DNA-binding activity of STAT3 but 
not that of STAT1. 
The effects of inS3-54 analogues on the DNA-binding activity of STAT3 (A, C and 
E) and STAT1 (B, D and F) were assessed by EMSA. The whole cell lysates 
extracted from H1299 cells transiently transfected with constitutively dimerizable 
FLAG-STAT3 or STAT1 were pre-incubated with increasing concentrations of 
inS3-54 analogues for 30 minutes prior to addition of [32P]-labeled double strand 
DNA probe that contains a STAT3 DNA-binding site for 20 minutes at room 
temperature. The reaction mixtures were then resolved on 6% non-denaturing 
polyacrylamide gel and detected by autoradiography. The binding of STAT3 to 
specific probe was inhibited following treatment with three analogues.  
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C. InS3-54 analogues bind to STAT3. 
In the previous studies, inS3-54-conjugated beads pulled down STAT3 from 
whole cell lysate, suggesting inS3-54 may bind to STAT3. To verify if these 
analogues (A18, A26 and A69) indeed bind to STAT3, compound-conjugated 
beads were also used to detect their potential interaction with STAT3 protein. A26 
containing an imino group was conjugated to CNBr-activated Sepharose 4B. 
Figure 24A shows that A26-conjugated beads successfully pulled down STAT3 
whereas the vehicle control beads (DMSO) or an irrelevant compound control 
(PHP) did not. Furthermore, pretreatment of the cell lysate using excess free A26 
abrogated the pull down of STAT3 by A26-conjugated beads while the inactive 
analogue had no effect (Figure 24B). Although Sepharose beads are available to 
conjugate A18 and A69, the competitive experiment was used to provide indirect 
evidence for their potential interaction with STAT3. Results shows that 
pretreatment of A26-conjugated beads with A18 and A69 also diminished the pull 
down of STAT3 from cell lysate (Figure 24C). Based on the above analyses, the 
inS3-54 analogues (A18, A26 and A69) may have the potential interaction with 
STAT3. 
Due to the similar property of the chemical structures compared to the 
STAT3 alkylating agent as previously described, we chose one of inS3-54 
analogues, A18, to determine whether it may act as an alkylating agent by using 
glutathione as a substrate accordingly. Similar to inS3-54, A18 did not affect the 
level of glutathione in both lung cancer A549 cells and breast cancer MDA-MB-
231 cells after exposure to 10 µM A18 for 48 hours (Figure 25), suggesting that 
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the interaction between A18 and STAT3 may not due to alkylation of cysteine 
residues in STAT3 under the condition tested.  
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Figure 24. Binding of inS3-54 analogues to STAT3. 
(A) Pull-down assay of STAT3 from total lysate of constitutively dimerizable FLAG-
STAT3-transfected H1299 cells using CNBr-activated Sepharose 4B-conjugated 
with vehicle control, A26 or irrelevant negative control compound (PHP). Pull-down 
samples were analyzed using SDS-PAGE and Western blotting probed with anti-
FLAG antibody. (B) Competition of STAT3-binding to A26-conjugated CNBr-
activated Sepharose 4B beads by excess free A26, an irrelevant compound control 
or vehicle control (DMSO). (C) Competition of STAT3-binding to A26-conjugated 
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CNBr-activated Sepharose 4B beads by excess free A18, A69 or vehicle control 
(DMSO). Unbound flow-through samples were used as the input control. All three 
compounds show the potential to bind to STAT3 protein.  
133 
 
Figure 25. A18 does not alkylate cysteine using glutathione as a substrate. 
After A549 and MDA-MB-231 cells were exposed to DMSO (0.1%) or 10 µM A18 
for 48 hours or 15 mM IAA for 30 minutes, the level of glutathione was assessed 
by GSH-GloTM glutathione assay following the manufacturer’s instructions. IAA 
was used as a positive control. The level of glutathione was not significantly 
affected by A18 under the condition tested. (N=3; *** p<0.001, by Student’s t-test 
as compared with DMSO vehicle control)  
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D. InS3-54 analogues favorably inhibit cancer cell survival possibly by 
inducing apoptosis. 
To determine whether the analogues (A18, A26 and A69) inhibit the survival 
of cancer cells with constitutive STAT3 signaling, the effects of various analogues 
on cell viability were analyzed in two lung cancer cell lines (A549 and H1299) and 
two breast cancer cell lines (MDA-MB-231 and MDA-MB-468) as well as a normal 
lung fibroblast cell line (IMR90) and a normal mammary epithelial cell line 
(MCF10A1) as measured by SRB assay. Our previous study demonstrated that 
these cancer cells harbor constitutively activated STAT3 as assessed by its 
phosphorylation status at Tyr705 compared to the normal cells (Figure 12A). 
Cancer cells appeared to be more sensitive to the analogues than the non-
tumorigenic cells with lower IC50 (1.8~5.6 µM vs 4.0~12.0 µM; Table 6), consistent 
with inS3-54. However, all three analogues showed comparable or more potent 
activity on inhibition of cancer cell proliferation as compared to the parental 
compound inS3-54 (Figure 26 and Table 6). 
To investigate whether apoptosis contributes to loss of tumor cell viability, 
the same ELISA which was used to determine the effect of inS3-54 on apoptosis 
was also used to evaluate the three analogues following treatment in exponentially 
growing cells. After A549 and MDA-MB-231 cells were exposed to DMSO control 
(0.1%), A18 or A69 for 72 hours, a remarkable induction of apoptosis was induced 
in both lung and breast cancer cells, suggesting that apoptosis probably 
contributes to suppression of cancer cell survival (Figure 27).  
135 
 
Figure 26. (Continued)  
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Figure 26. (Continued)  
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Figure 26. InS3-54 analogues inhibit cancer cell proliferation. 
A variety of lung and breast cell lines were treated with the indicated 
concentrations of A18 (A-B), A26 (C-D) or A69 (E-F) for 72 hours followed by SRB 
assay. Cancer cell lines are more sensitive to inS3-54 analogues compared to 
normal cell lines.  
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Figure 27. InS3-54 analogues induce apoptosis. 
Exponentially growing A549 and MDA-MB-231 cells were treated with A18 (A) or 
A69 (B) for 72 hours followed by determination of apoptosis using ELISA. 
Apoptosis was induced after exposure to both compounds in A549 and MDA-MB-
231 cells. (N=3; * p<0.05, ** p<0.01, by Student’s t-test as compared with DMSO 
control)  
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E. Rationale for focusing on A18 in the following experiments  
Although inS3-54 represents our first attempt to develop small molecule 
compounds targeting the DBD of STAT3, it may not be an ideal candidate 
compound for further development of specific STAT3 inhibitors due to low 
specificity for the DBD of STAT3 protein. Fortunately, all three active analogues 
(A18, A26 and A69) are likely specific to STAT3 protein as determined by in vitro 
colony formation assay using cells isolated from wild-type and STAT3-/- mice. Their 
effects on DNA-binding activity of STAT3 and cell survival are also more potent or 
comparable than inS3-54. Of four compounds, inS3-54, A26 and A69 have very 
poor solubility in available vehicles used for in vivo animal studies although they 
can be completely solubilized in DMSO for in vitro experiments, suggesting their 
limitation for in vivo efficacy test (Table 7). A pilot toxicity study found that A69 was 
toxic as low as 0.5 mg/Kg. Moreover, despite inS3-54 and A26 may be tolerant in 
mice up to 100 mg/Kg and 200 mg/Kg respectively, a pilot PK study indicated that 
the maximum plasma concentration of inS3-54 only achieved 445~456 ng/mL 
(equivalent to ~2 μM) by one-time dosing of inS3-54 in homemade or commercial 
formulations (Table 8). The plasma concentration of A26 was even undetectable 
when mice were administrated by intraperitoneal injection of 200 mg/Kg A26. 
However, A18 can be completely solubilized in a commercial oral dosing 
formulation up to 100 mg/mL, facilitating the following efficacy studies (Table 7). 
Combined with the data obtained from the above cellular assays, we decided to 
focus on A18 in the following studies.  
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Table 7. Observation of solubility of each compound in 
formulations commonly used for in vivo studies 
Formulation inS3-54 A18 A26 A69 
4%  ethanol:cremophor 
(1:1) 
Partially 
dissolved, best 
in homemade 
formulations 
tested 
Partially 
dissolved 
Partially 
dissolved, best 
in homemade 
formulations 
tested 
/ 
20% PEG 400 Not dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
50% PEG 400, 10% 
ethanol, 10% cremophor 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
20% PEG 400, 10% 
cremophor 
Partially 
dissolved 
Partially 
dissolved 
Not dissolved / 
20% PEG400, 10% 
ethanol, 1% Tween-80 
Partially 
dissolved 
Partially 
dissolved 
Not dissolved / 
15% DMSO Not dissolved Not dissolved Not dissolved / 
Methylcellulose Not dissolved Not dissolved Not dissolved / 
2-hydroxy-β-cyclodextrin 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 1-
Formulation 1 (HRC-K1-1) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 1-
Formulation 2 (HRC-K1-2) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 1-
Formulation 3 (HRC-K1-3) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 1-
Formulation 4 (HRC-K1-4) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 1-
Formulation 5 (HRC-K1-5) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 1-
Formulation 6 (HRC-K1-6) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 1-
Formulation 7 (HRC-K1-7) 
Milk-like 
suspension, 
best in Kit 1 
Milk-like 
suspension 
/ 
Milk-like 
suspension, 
best in Kit 1 
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Hot Rod Chemistry Kit 1-
Formulation 8 (HRC-K1-8) 
Milk-like 
suspension 
Milk-like 
suspension 
/ 
Milk-like 
suspension 
Hot Rod Chemistry Kit 2-
Formulation 1 (HRC-K2-1) 
Partially 
dissolved 
Completely 
dissolved up 
to 100 mg/mL 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 2 (HRC-K2-2) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 3 (HRC-K2-3) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 4 (HRC-K2-4) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 5 (HRC-K2-5) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 6 (HRC-K2-6) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 7 (HRC-K2-7) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
Hot Rod Chemistry Kit 2-
Formulation 8 (HRC-K2-8) 
Partially 
dissolved 
Partially 
dissolved 
Partially 
dissolved 
/ 
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Table 8. Toxicity and PK characteristics of inS3-54 and its analogues 
Compound Formulation 
Route of 
administration 
Tolerance 
Maximum plasma 
concentration 
inS3-54 
Hot Rod Chemistry Kit 
1-Formulation 7 (HRC-
K1-7) 
i.p. 
Up to 100 
mg/Kg 
445 ng/mL* 
4%  ethanol:cremophor 
(1:1) 
i.p. 
Up to 100 
mg/Kg 
456 ng/mL* 
A18 
Hot Rod Chemistry Kit 
2-Formulation 1 (HRC-
K2-1) 
p.o. 
Up to 200 
mg/Kg 
/ 
A26 
4%  ethanol:cremophor 
(1:1) 
p.o. 
Up to 200 
mg/Kg 
Undetectable 
A69 
Hot Rod Chemistry Kit 
1-Formulation 7 (HRC-
K1-7) 
i.p. 
Lower than 
0.5 mg/Kg 
/ 
* Equivalent to ~2 μM calculated on ~2 mL of total blood volume in mice.  
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F. A18 inhibits cancer cell migration and invasion. 
Our previous study has suggested that the parental compound inS3-54 
inhibits cancer cell migration and invasion by down-regulating the expression of 
STAT3 downstream targets. To assess the effects of A18 on cancer cell migration 
and invasion, wound-filling assay was first performed in A549 and MDA-MB-231 
cells following the treatment with 0.1% DMSO, 5 and 10 µM A18 for 24 hours. 
Figure 28 shows that A18 inhibited migration of both A549 and MDA-MB-231 cells 
in a dose- and time-dependent manner. At 24 hours, 71% and 99% of wound were 
filled in absence of A18 in A549 and MDA-MB-231 cells, respectively; whereas 64% 
and 76% of wound were filled following 5 µM A18 treatment in both cell lines, 
respectively. Moreover, the wounds were only covered 47% and 39% respectively 
after both cell lines were exposed to 10 µM A18. 
Cell invasion was determined using Matrigel invasion assay after A549 or 
MDA-MB-231 cells were exposed to 0.1% DMSO, 5 and 10 µM A18 for 6 or 24 
hours. As shown in Figure 29, 5 µM A18 inhibited 66% and 51% of invasion at 6 
hours in A549 and MDA-MB-231 cells, respectively, as compared to the vehicle 
control. After 24-hour treatment, the cell invasion was reduced to 60% and 36% in 
both cell lines, respectively. 10 µM A18 suppressed cell invasion to 35% and 13% 
at 6 hours in both cell lines, respectively, compared to DMSO control, while the 
cell invasion only achieved 25% and 11% after 24 hours. Significant difference 
(p<0.05) between A18 and DMSO vehicle was evident by 6 hours in A549 and 
MDA-MB-231 cells.  
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Similar to inS3-54, although 100% confluent cells and relative short 
incubation time were applied to the above assays, A18 inhibition of proliferation 
may still contribute to the above observed outcome. To eliminate this possibility, 
we analyzed cell proliferation and apoptosis under the same condition as wound 
filling and Matrigel invasion assays with confluent cultures. Figure 30 showed that 
treatment with 5 and 10 µM A18 for 6 or 24 hours had no significant effect on 
proliferation and apoptosis of confluent A549. Although total cell number 
decreased following the treatment with 10 µM A18 for 24 hours in MDA-MB-231 
cells, the fold change remained at only 20% and cell migration and cell invasion 
were significantly reduced under this condition (Figure 28-29). Thus, it is 
concluded that A18 inhibition of migration and invasion is unlikely due to its effect 
on apoptosis and cell proliferation and A18 can inhibit migration and invasion of 
lung and breast carcinoma cells.  
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Figure 28. (Continued)  
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Figure 28. (Legend on next page) 
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Figure 28. A18 inhibits cancer cell migration. 
Migration of A549 (A-B) and MDA-MB-231 (C-D) cells was assessed by wound 
filling assay in the presence of 0.1% DMSO  or A18 for 24 hours. Quantification 
analyses of wound filling assay were derived from three independent experiments 
as shown in Panel B and D. Cell migration was reduced following A18 treatment 
in both cell lines.  
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Figure 29. (Continued) 
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Figure 29. A18 inhibits cancer cell invasion.    
The invasion of A549 (A-B) and MDA-MB-231 (C-D) cells were determined in the 
presence of DMSO (0.1%), 5 or 10 µM A18 for 6 or 24 hours using Matrigel 
invasion assay with 10% FBS in the bottom chamber as a chemoattractant. As 
shown in Panel B and D, quantification of invasion came from measurement of 10 
random views each of three independent experiments. Cell invasion was 
suppressed after exposure to A18 in both cell lines. (N=3; * p<0.05, ** p<0.01, *** 
p<0.001, by Student’s t-test as compared with DMSO vehicle control)  
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Figure 30. (Continued)  
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Figure 30. Effects of A18 on cell growth and apoptosis of confluent cells. 
100% confluent A549 (A and C) and MDA-MB-231 (B and D) cells were treated 
with DMSO (0.1%), 5 or 10 µM A18 for 6 or 24 hours followed by determination of 
change in cell number for proliferation (A-B) or ELISA for apoptosis (C-D). In 
addition to 10 µM treatment in MDA-MB-231 cells for 24 hours, A18 had no effect 
on the growth and apoptosis of confluent cells. (N=3; ** p<0.01, ** p<0.001, by 
Student’s t-test as compared with DMSO vehicle control)  
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G. A18 inhibits the expression of STAT3 downstream target genes and 
STAT3 binding to its endogenous target sequences. 
To investigate the potential effect of A18 on STAT3 downstream targets and 
thereby verify its inhibitory effect on STAT3 in cells, we further examined the 
expression level of known STAT3 downstream targets by using Western blot and 
real-time PCR analyses following A18 treatment in A549 and MDA-MB-231 cells. 
As shown in Figure 31A-C, the expression of cyclin D1, survivin, MMP-9 and 
VEGF were all decreased in the presence of A18 in both cell lines whereas the 
levels of phospho-STAT3 (Tyr705) and total STAT3 were not affected. Selected 
genes were also confirmed by real-time PCR in both cell lines (Figure 31D-E). 
In addition to constitutively activated STAT3, we also determined whether 
or not A18 is capable of inhibiting cytokine-induced STAT3 phosphorylation. After 
starved A549 cells were pre-treated with DMSO control (0.1%) or 10 µM A18 
followed by IL-6 stimulation, phospho-STAT3 (Tyr705) expression was not 
changed obviously with or without A18 pretreatment. One of STAT3 target genes, 
survivin, was elevated by 14 folds in IL-6 treated cells pre-treated with DMSO, 
whereas IL-6 induced survivin expression was also abrogated by 41% following 
A18 treatment (Figure 32). The results indicate that A18, which is designed to 
target the STAT3 DBD, may not affect the expression or activation of constitutive 
STAT3 or IL-6-induced STAT3 but represses the expression of STAT3 target 
genes. 
To further demonstrate that A18 inhibits the DNA-binding activity of STAT3 
in cells, A549 and MDA-MB-231 cells were exposed to DMSO (0.1%), 5 or 10 µM 
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A18 followed by fractionation of cytosol, soluble nuclear fraction and chromatin-
bound proteins. The STAT3 levels in these fractions were investigated by Western 
blot analysis. As shown in Figure 33, the chromatin-bound STAT3 decreased 
while the STAT3 level in soluble nuclear fraction increased with the increasing 
concentrations of A18. This result was also verified by determination of STAT3 
binding to the promoter regions of two STAT3 downstream targets (cyclin D1 and 
twist) using ChIP assay. Data indicate that A18 effectively inhibits the binding of 
STAT3 to its endogenous target sequences on genomic DNA in situ (Figure 34). 
Taken together with the results shown above, we conclude that A18 specifically 
inhibits STAT3 activity in binding to endogenous promoters on genomic DNA, 
resulting in reduced transcription of its downstream target genes.  
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Figure 31. (Continued)  
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Figure 31. A18 inhibits the expression of STAT3 downstream target genes. 
(A-C) A549 and MDA-MB-231 cells were exposed to DMSO (0.1%) or 10 µM A18 
followed by lysate preparation and Western blot analysis with antibodies indicated. 
β-actin was used as a loading control. Panel B and C shows the quantitative data 
of each protein measured by the density of Western blot bands and normalized 
against the β-actin internal control. (N=3; * p<0.05, ** p<0.01, by Student’s t-test 
as compared with DMSO vehicle control) (D-E) A549 and MDA-MB-231 cells were 
treated with DMSO (0.1%) or 10 µM A18 followed by total RNA extraction and real-
time PCR analysis. Data show the relative mRNA levels normalized to the internal 
control, GAPDH. (N=4; * p<0.05, by Student’s t-test as compared with DMSO 
156 
vehicle control) All results suggest that A18 inhibited the protein and mRNA levels 
of STAT3 downstream targets in both cells lines.  
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Figure 32. A18 does not affect IL-6 induced STAT3 phosphorylation. 
A549 cells were cultured in serum-free medium for 2 days and then pre-treated 
with 10 µM A18 for 12 hours followed by 25 ng/mL of IL-6 for 30 minutes. After 
treatment, the expression levels of phospho-STAT3, STAT3 and survivin were 
examined by Western blot analysis. A18 had no effect on IL-6-induced activation 
of STAT3. However, IL-6 stimulated survivin was reduced by 41% following A18 
treatment.  
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Figure 33. A18 inhibits STAT3 binding to chromatin. 
A549 and MDA-MB-231 cells were treated with DMSO (0.1%), 5 or 10 µM A18 for 
72 hours followed by fractionation of cytosol, soluble nuclear fraction, and 
chromatin-bound proteins and Western blot analysis of STAT3 in these fractions. 
A18 blocked the binding of STAT3 to genomic DNA.  
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Figure 34. A18 inhibits the binding of STAT3 to the promoter regions of 
responsive genes. 
H1299 cells were treated with 0.1% DMSO or 10 µM A18 for 24 hours followed by 
ChIP assay and agarose gel electrophoresis. No antibody and IgG were used as 
background negative control. A18 suppressed the binding of STAT3 to the 
promoter regions of cyclin D1 and twist.  
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H. A18 inhibits tumor growth in vivo. 
A mouse xenograft model of human lung cancer was used to investigate 
the in vivo efficacy of A18. Mice were treated with vehicle or A18 every other day 
for 30 days and tumor volume was measured overtime by caliper. On day 35 post-
implantation, the mice were euthanized and the tumor tissues were harvested, 
weighed, and processed for immunohistochemistry analyses. One mouse in each 
group (vehicle and A18) was found dead during drug administration and thus 
excluded from data analyses. Due to variation in mice, outlier data were also 
rejected by Dixon's Q test at 95% confidence. Following oral dosing of 200 mg/Kg 
A18, the tumor volume in the A18-treated group reduced to 237.1 mm3 whereas 
that in the vehicle-treated group achieved 438.2 mm3 (Figure 35A). The tumor 
weight of A18-treated group (0.239±0.076 g) was also lower than that of vehicle 
control group (0.561±0.266 g) with p=0.53. However, the body weight had no 
significant difference between both groups during drug administration (Figure 
35B). Furthermore, necropsy found that no obvious abnormality was visible in the 
heart, lungs, kidneys, liver and spleen. The weight of each organ also showed no 
statistically significant difference although the liver weight of A18-treated group is 
slightly lower than that of vehicle control group (Figure 35C). H&E staining and 
histology evaluation showed that 3 of 5 mice in the vehicle control group developed 
secondary tumors in lung tissues with extension into the peripancreatic adipose 
tissues and the adjacent peripancreatic lymph nodes while none of A18-treated 
mice showed tumor metastasis in lungs (Figure 36). 
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Furthermore, expression of STAT3, survivin and VEGF in the xenograft 
tumors was determined by immunohistochemistry staining. As shown in Figure 37, 
total STAT3 showed no difference in tissues obtained from both vehicle control 
group and A18-treated group. Importantly, two STAT3 downstream targets, 
survivin and VEGF showed decreased staining in A18-treated tumors. Given that 
A18 was found to inhibit STAT3-depedent gene expression by blocking the binding 
of STAT3 to the promoter regions of downstream genes whereas the total STAT3 
level was not affected following A18 treatment as demonstrated by a variety of 
cellular assays, these results may also indicate the in vivo inhibition of A18 on the 
expression of STAT3 downstream genes. Taken together, these data suggest the 
potential value of A18 for development of specific STAT3 inhibitor as a novel anti-
neoplastic drug. 
Although the pilot study is usually designed based on experience or guess 
work, the results of the pilot study can also be used to determine the minimal 
sample size in the future animal studies. The sample size required in each group 
for further studies was finally estimated as described previously (126). While 
comparing the means μ1 and μ2 from two independent groups, it is assumed to 
follow normal distribution, homogeneous variances, equal sample sizes and a two-
sided test. The false positive rate is set to α, and the power to detecting a difference 
∆=| μ1-μ2 | is set to 1-β, where β is the false negative rate. Defining α=0.05 and 
β=0.20, the sample size required in each group (n) is: 
n = 
2 (𝑍𝛼/2 + 𝑍1−𝛽)
2
(
∆
𝜎
)2
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where the constant Zα/2 represents the desired level of statistical significance 
(typically 1.96 for 0.05 significance),  the constant Z1-β represents the desired 
power (typically 0.84 for 80% power), σ = √
𝜎1
2+ 𝜎2
2
2
, representing the standard 
deviation of the outcome variable, and ∆=| μ1-μ2 |, representing the effect size (the 
difference in means). 
Based on the pilot study, μ1=0.561 g, μ2=0.239 g, σ1=0.266 g, σ2=0.076 g, 
thus 
n =  
2×(1.96 + 0.84)2
(
0.561−0.239
0.196
)2
 = 5.80 
Considering 10% drop-out rate, n = 5.80 × 110% = 6.39 ≈ 7. 
Therefore, the minimal 7 mice per group shall be used in the following 
studies, giving 80% power at the 0.05 level of significance.  
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Figure 35. (Legend on next page) 
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Figure 35. A18 reduces tumor growth in vivo. 
Six mice in each group were administrated with oral dosing of vehicle control or 
200 mg/Kg A18 every other day. Tumor volume and body weight were recorded 
twice per week during drug treatment. The tumor weight was measured on the 35th 
day post-implantation. Outliers (one mice in each group) were rejected by Dixon's 
Q test at 95% confidence. A18 reduced tumor growth with little effect on body 
weight or indicated organs. (N=4; * p<0.05, by Student’s t-test as compared with 
vehicle control)  
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Figure 36. A18 reduces lung metastases in a mouse xenograft model of lung 
cancer. 
A549 cells were implanted in the flanks of 12 NOD/SCID mice. 30 days after drug 
administration, lung tissues were harvested and prepared for paraffin-embedded 
tissue sections, followed by H&E staining. H&E-stained paraffin sections of lung 
tissues obtained from vehicle control group and A18-treated group were finally 
evaluated by an experienced pathologist. Arrow indicates a solitary tumor 
developed in the lung tissue of a vehicle control mice.  
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Figure 37. A18 reduces the expression of STAT3 downstream targets in vivo. 
A549 cells were implanted in the flanks of 12 NOD/SCID mice. 30 days after drug 
administration, tumor tissues were harvested and prepared for paraffin-embedded 
tissue sections, followed by immunohistochemistry staining. A18-treated groups 
showed decreased expression of surviving and VEGF. Total STAT3 showed no 
difference in both groups of mice.  
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IV. Discussion 
A. Contribution of the present study 
The present study demonstrates the feasibility of computational screening 
approach to identify potential small molecule inhibitors that target the DBD of 
STAT3. Of a total of about 200,000 virtual compounds, inS3-54 showed 
remarkable inhibition on STAT3-dependent luciferase reporter activity, DNA-
binding activity of STAT3, cancer cell survival, cell migration and invasion as well 
as STAT3-mediated gene expression. By directly binding to STAT3, inS3-54 
prevented the binding of STAT3 to the promoter regions of responsive genes, 
thereby resulting in down-regulation of expression of STAT3-dependent genes 
such as cyclin D1 and twist. Furthermore, inS3-54 did not affect STAT3 
dimerization or the constitutive/IL-induced activation of STAT3. Subsequently, the 
analogues of inS3-54 were also developed to investigate the structure-activity 
relationship. Of 89 analogues, A18, A26 and A69 showed more potent or 
comparable effects on persistent STAT3 signaling. In particular, the three active 
analogues were more selective to STAT3 protein than inS3-54 as demonstrated 
by in vitro colony formation assay using cells isolated from STAT3+/+ and STAT3-/- 
mice. We further investigated the molecular mechanism of A18 because of its 
acceptable solubility for animal studies and then verified its inhibitory effects on 
DNA-binding activity of STAT3 in cells. Importantly, A18 reduced tumor growth in 
a mouse xenograft model of lung cancer and had little effects on body weight with 
no abnormality on heart, lungs, kidneys, liver and spleen. Collectively, these data 
provide compelling evidence that A18 represents a potential lead compound for 
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further development to inhibit the constitutively activated STAT3 signaling by 
targeting the DBD of STAT3. 
 
B. Challenges to target STAT3 
Irregular transcription factor activity leads to profound and sustained 
phenotypic effects in cells by altering the gene expression, thereby making this 
class of proteins highly desirable targets for therapy. An increased knowledge of 
the transcription mechanisms and the transcriptional regulatory networks has led 
to a better understanding of their critical roles in cancers. Generally, strategies for 
targeting transcription factors include inhibiting their functional domains and 
inhibiting the post-translational modifications that modulate their function. However, 
successfully blocking the activity of transcription factors remains challenging. The 
protein-protein interactions or the protein-DNA interfaces usually have large or flat 
surface area of the target, thereby providing insufficient cavities to develop small 
molecule antagonists with high affinity. The complexity of the interactions involving 
multi-point contact over large surfaces leads to difficulties to design small 
molecular inhibitors. It is very likely to require a large molecule to block the entire 
surface, leading to the poor membrane permeability and the consequential low 
biological activity in cells. Furthermore, a transcription factor which binds to 
negatively charged DNA may tend to be positively charged. A molecule targeting 
a transcription factor thus needs to be negatively charged, causing the potential 
poor membrane permeability. Despite these obstacles, a few of these efforts 
towards targeting transcription factors have been reported, including targeting 
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nuclear factor-κb (NF-κb), p53, Notch, Nrf2, etc (127-129). Approximately 10% of 
currently prescribed drugs directly target the nuclear receptor class of transcription 
factors such as tamoxifen and bicalutamide (130). Although no inhibitors targeting 
transcription factors outside the nuclear receptor family has been approved, clinical 
trials targeting p53 or NF-κb are currently performed for several types of cancer 
(127-129). 
STAT3 is a well-known oncogenic protein which acts as a transcription 
activator in cells. Obviously, the intense development of STAT3 inhibitors never 
ceases. A large number of STAT3 inhibitors obtained from peptidomimetic design, 
high-throughput screening, fragment-based drug design and structure-based 
virtual screening, reflecting a significant research area (56, 61, 62). The majority 
of STAT3 inhibitors are directed at the SH2 domain, which is important for receptor 
recognition and dimerization of STAT3 by reciprocal binding to Tyr705 (69-81). 
However, most inhibitors targeting SH2 domain are still not close to clinical 
application due to their moderate cellular activity. One of the important issues may 
be attributed to the protein-protein interaction as a targeting site. Since the classic 
phosphotyrosine residue-SH2 domain interface is located at Lys591, Arg609, 
Ser611 and Ser613 via direct interaction, most SH2 inhibitors usually target these 
critical residues (36). However, structural similarity with other proteins may be also 
challenging for development of specific inhibitors. SH2 domain of STAT3 is a highly 
conserved region which has a high sequence similarity to other proteins including 
Src, phospholipase C-γ, phosphatidylinositol 3-kinase and other STATs (131, 132). 
Moreover, STAT1 and STAT3 share extensive structural homology and their 
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crystal structures are virtually superimposable, however, they appear to play 
opposite roles in tumorigenesis (119). STAT3 inhibitors thus have to be assessed 
for the selectivity on STAT3 over STAT1. And the specificity of inhibitors is a key 
issue that must be clearly addressed. In addition, it has been recently found that 
unphosphorylated STAT3 can bind to specific enhancer sequences and thereby 
contribute to gene expression (82-85). Unphosphorylated STAT3 may have a 
mechanism distinct from phospho-STAT3. For example, it was found to activate 
NF-κb-regulated genes by directly binding to unphosphorylated NF-κb via its SH2 
domain (84). Although more studies are needed to investigate the detailed 
mechanism and the potential interaction with other proteins, we may speculate that 
the disruption of protein-protein interactions may be complicated and thus 
challenging. Therefore, disrupting the dimerization of STAT3 molecules alone may 
not be enough to completely inhibit aberrant STAT3 activity in cancer cells.  
On the other hand, DBD has gotten far less attention to date than the 
dimerization disruption. As mentioned above, many DNA-binding proteins such as 
transcription factors are considered undruggable because their active DNA-
binding sites are too shallow or too similar to permit specific and tight binding of 
small molecules to their DBDs. Nevertheless, the inhibition of the DNA-binding 
activity of STAT3 for drug discovery has been tested. In particular, the Phase 0 
clinical trial of STAT3 decoy ODN has been recently reported to demonstrate the 
feasibility of blocking DNA binding of STAT3 in humans (99). The main limitation 
of decoy ODNs remains their pharmaceutical properties due to the nature of these 
biological agents. Some compounds are presumed to inhibit aberrant STAT3 
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signaling by blocking the protein-DNA interaction, however, a few successful 
strategic plans directed at this site have been reported. Either the exact modes of 
inhibition of STAT3 remain unclear or the compounds may interact with other 
proteins or affect other signaling pathways (86-93). More efforts to develop 
effective and selective STAT3 inhibitors may achieve success to develop the 
clinically appropriate drugs. 
 
C. Targeting of inS3-54 and its analogues to STAT3 
Specificity is one of the critical challenges to develop an ideal STAT3 
inhibitor which targets STAT3 protein without affecting other proteins such as 
upstream molecules or other STAT members. In this study, we made a great effort 
to develop a small molecule STAT3 inhibitor with good efficacy and specificity. 
Screening of large chemical libraries is expected to acquire compounds with drug-
like, assay-compatible and toxicity-free properties. In the process of virtual 
screening, the initial hit, inS3-54, was originally identified by virtual compound 
screening and STAT3-dependent luciferase reporter assay to bind to the DBD of 
STAT3. To ensure the membrane permeability in cells, the small molecule 
compounds that contain phosphate groups mimicking phosphates in DNA were 
eliminated. We also docked the potential candidate compounds onto the DBD of 
STAT1 to eliminate any compounds that may bind to STAT1. Subsequently, 100 
potentially specific candidates were selected for in vitro screening using STAT3-
dependent luciferase reporter assay. After the initial hit inS3-54 and its analogues 
(A18, A26 and A69) were identified, these compound were also tested by STAT3-
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independent luciferase reporter assay. The finding that inS3-54 and three 
analogues did not inhibit the promoter activity of p27 indicates that these 
compounds may not exhibit the inhibition of luciferase reporter due to non-specific 
effects on the expression or activity of reporter gene. 
A series of experiments were then performed to verify whether or not inS3-
54 and its analogues target STAT3 specifically. First of all, in-silico analysis shows 
that inS3-54 binds to the residues Met331, Val343, Met420, Ile467 and Met470 of 
STAT3 via hydrophobic interaction with the aid of Lys340 and Asn466 to stabilize 
the carboxyl group of inS3-54 by favorable electrostatic interaction. Meanwhile, 
inS3-54 could not bind to STAT1 due to physical hindrance from residue Pro326 
and Thr327, leading to a much lower affinity to STAT1. Moreover, EMSA 
demonstrates that inS3-54 and three analogues appear to be selective to STAT3 
over STAT1. The less cytotoxic effect of these compounds on normal lung 
fibroblast and mammary epithelial cells than malignant cells harboring persistent 
activation of STAT3 further confirms the above observation, as determined by SRB 
assay. It is noteworthy that these compounds showed IC50 of 8.8~13.8 µM in 
luciferase reporter assay. However, the IC50 of inS3-54 in cytotoxicity assay is 
ranged from 1.8~5.6 µM in cancer cells to 4.0~12.0 µM in normal cells. Currently, 
it is unknown why the compounds are more effective in inhibiting cell survival than 
inhibiting luciferase reporter expression. It is possible that the cytotoxicity assay is 
more sensitive as it measures both proliferation and cell death induced by the 
compounds, which is an amplified result of reduced expression of STAT3 
downstream target genes. It is also possible that the compounds may have off-
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target effects that may impact on cell survival. Additionally, we attempted to 
investigate the direct interaction between these compounds and STAT3 protein. 
The compound-conjugated beads were prepared for a pull down assay to identify 
the potential binding between STAT3 and these compounds. The finding that inS3-
54 or A26-conjugated beads pulled down STAT3 from whole cell lysate verifies the 
potential compound-protein interaction. Although there are no available beads for 
conjugation of A18 and A69, a competition assay indicates they may bind to 
STAT3 by using A26-conjugated beads with pretreatment of excess A18 or A69. 
It is noted that the commercial human recombinant STAT3 protein was observed 
to bind to inS3-54-conjugated beads, suggesting the direct interaction between 
inS3-54 and STAT3 protein. However, the silver staining result of pull down assays 
using whole cell lysates revealed multiple bands for inS3-54. It is possible that 
multiple proteins come with STAT3 pull-down or inS-54 causes off-target effects 
by binding to other proteins. Thus, we suspected whether these compounds have 
promiscuous multi-target effects eventually based on the above results. 
Subsequently, a STAT3-dependent colony formation assay using bone marrow 
hematopoietic progenitor cells offers a  useful tool to identity the specificity profile 
that correlates with the blockade of constitute STAT3 activity on basis that specific 
STAT3 inhibitors do not affect the colony formation of mouse bone marrow cells 
from mice with conditional knock-out of STAT3. In addition to the initial hit, inS3-
54, all three analogues were found to inhibit colony formation of STAT3+/+ 
hematopoietic progenitor cells but not STAT3-/- cells, suggesting their selectivity 
on STAT3 relative to other targets that are important for colony formation of 
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hematopoietic progenitor cells. Furthermore, as determined in Figure 22, inhibition 
on colony formation of wild-type hematopoietic progenitor cells may predict the 
potential toxicity of these compounds in animals, e.g. myelosuppression. However, 
no significant toxicity was observed in A18-treated mice. Indeed, the dosage of 
A18 (200 mg/Kg), which is equivalent to ~5 μM calculated on ~2 mL of blood 
volume in mice, may not be comparable to the concentration (20 μM) used in 
colony formation assay even though the bioavailability achieves 100% in mice. 
Overall, our studies provide an attempt on preclinical studies and we believe these 
observations suggest A18 may emerge as a promising antineoplastic agent with 
further exploration. 
All specific inhibitors identified from virtual screening need to be further 
characterized to elucidate their actual binding mode. A troubling trend is the fact 
that a number of small molecule inhibitors of STAT3 have a reactive chemical 
moiety in common (56, 61, 62). Various STAT3 inhibitors can be classified as 
Michael acceptors processing vinyl sulfone and α,β-unsaturated ketone 
functionalities. For example, it is possible that C18 which alkylates Cys468 on the 
DBD is capable of modifying cysteine residues through the Michael reaction, which 
could result in any surface-exposed cysteine residues being available for inhibitor-
medicated alkylation as well (93). Interestingly, many SH2 inhibitors also exhibit 
similar features, e.g. S3I-201 and stattic. Some compounds identified by such 
structural features appear to be identified frequently by high throughput screening. 
These compounds are promising for initial exploration, whereas they usually do 
not progress fun in the analysis pipeline. Despite containing a Michael acceptor 
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group, inS3-54 and A18 do not alkylate the thiol group of cysteine as determined 
by the glutathione assay and the binding of STAT3 to inS3-54-conjugated beads 
can be reversed by elution with excess free compound. These data indicate that 
the binding of STAT3 to compound-conjugated beads is not due to covalent 
binding and our compounds most likely do not act as an alkylating agent. In the 
future, nuclear magnetic resonance spectrum analysis or protein-ligand binding 
assay such as surface plasmon resonance analysis will facilitate more critical 
evaluation of these compounds and drive more information regarding their key 
structural determinants in the future. 
 
D. Structure-activity relationship of inS3-54 and its analogues 
Based on the current results of cellular assays, a further structure-activity 
relationship analysis reveals the features of these compounds that bind to the DBD 
of STAT3 (Figure 38). Firstly, inS3-54 and most of analogues contain a core 
structure of 5-phenyl-1H-pyrrol-2(3H)-ketone. Interestingly, the manual 
modification of the core structure to ethyl-4-hyrodroxy-5-oxo-4,5-dihydro-1H-
pyrrole-3-carbonylate (A80~89) caused loss of activity of the compounds (Table 
6). Secondly, it appears that the activity of these compounds in inhibiting STAT3 
varies based on the modification of the R1 and R2 side groups in the core structure. 
As shown in Figure 7, the nitrobenzene at the R2 position of inS3-54 contributes 
to the binding of the residues Met331, Val343, Met420, Ile467 and Met470 of 
STAT3 via hydrophobic interaction. The carboxyl group on the benzene ring at R1 
position stabilizes the binding via electrostatic interaction with the residues Lys340 
176 
and Asn466 of STAT3. However, the docking of inS3-54 onto STAT1 is 
unfavorable with physical hindrance. Therefore, both R1 and R2 groups may be 
critical for the activity and specificity of these compounds. A general review of inS3-
54 analogues reveals that the STAT3 inhibitory activity of the compounds 
increased with the R2 group being nitrobenzene, p-chlorobenzene, benzenamine 
and p-methoxylbenzene, but decreased with R2 group being and 5-phenylfuran 
(Figure 21A and Table 5). The R1 group is also one of the important determinants 
of STAT3-inhibiting activity. The existence of p-hydroxyl, p-carboxyl and p-amide 
side groups on the benzene ring facilitated the activity of these compounds (Figure 
21A and Table 5). However, this relationship is not absolute; the activity of the 
compounds is more likely to depend on the combination of R1 and R2 side groups 
in the core structure. All three active analogues of inS3-54 exhibited more potent 
or comparable activity on inhibition of STAT3-dependent signaling, DNA-binding 
activity, and cancer cell survival than the initial hit and all compounds are specific 
to STAT3 protein as demonstrated by the colony formation assay of STAT3+/+ and 
STAT3-/- cells. It is also noteworthy that the specificity of the three active inS3-54 
analogues appears to be determined by the side group on 1-benzene ring at 4’-
position. While the STAT3 specific inhibitors A18, A26 and A69 have hydroxyl or 
amide groups at this position, the non-specific inhibitor inS3-54 has carboxyl group. 
Replacing the hydroxyl or amide groups by carboxyl group at this position may 
abolish the specificity of these compounds to STAT3 and enable them to bind to 
other proteins. Besides, the combination of various R groups may affect the in vivo 
properties. For example, a pilot pharmacokinetic study revealed a very low plasma 
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concentration of inS3-54 and A26 due to their poor solubility and absorption with 
much deposit in peritoneal cavity. A69 appears to work on STAT3 faster than other 
compounds with shortest time to achieve 50% inhibition on STAT3-dependent 
luciferase reporter (Figure 21C), but a pilot toxicity study reveals that the 
compound is toxic to mice with a tolerance dose of less than 0.5 mg/Kg (Table 8). 
However, A18 has acceptable activity on STAT3 signaling and good solubility of 
up to 100 mg/mL in a commercial vehicle for animal studies (Table 7). Eventually, 
the in vivo efficacy of A18 was assessed by a mouse xenograft model of lung 
cancer. The compound inhibited tumor growth in mice harboring A549 xenograft 
tumors via oral administration whereas it had little effect on total body weight and 
five main organs (Figure 35). However, additional SAR studies are needed to test 
the hypothesis that the various side groups determine the activity of compounds.  
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Figure 38. SAR analysis of inST3-54 analogues. 
Schematic core structure of inST3-54 and its peripheral groups. Representational 
functional groups are shown with indication of favorable (thick arrows) or 
unfavorable substitutions (thin-crossed arrows).  
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E. Mechanism of inS3-54 and its analogues 
As expected, these compounds inhibited constitutive STAT3 signaling by 
blocking the binding of STAT3 to the promoter regions of STAT3 responsive genes. 
In this study, inS3-54 and its analogues were found to inhibit cancer cell survival, 
migration and invasion as well as induce apoptosis after lung and breast cancer 
cells were exposed to the compounds. We thereby suggest that inhibition of 
STAT3 binding is a primary mechanism by which these compound exert antitumor 
effects in A594 and MDA-MB-231 cells. Firstly, STAT3 activation occurs by ligand 
binding to specific cell surface receptors (16). InS3-54 and A18 were found not to 
affect IL-6-induced STAT3 activation by detecting the phosphorylation status of 
STAT3, however, one of the STAT3 downstream targets, survivin, was still 
suppressed by inS3-54 or A18 in absence and presence of IL-6, suggesting these 
compounds have little effect on STAT3 activation. Furthermore, direct inhibition of 
STAT3 can be achieved via targeting one of three structural domains of STAT3 
such as SH2, DBD or N-terminal domains, resulting in inhibition of STAT3 signaling. 
InS3-54 was found not to inhibit STAT3 dimerization, indicating that it may not bind 
to the susceptible SH2 domain. To verify the inhibitory effects of these compounds 
on DNA-binding activity of STAT3 in cells, different cellular fractions were isolated 
from A549 and MDA-MB-231 cells following inS3-54 or A18 treatment. We are not 
surprised to find that inS3-54 and A18 blocked the binding of STAT3 protein to 
chromatin in both lung and breast cancer cells. The total level of STAT3 and the 
level of STAT3 in cytosol fraction remained stable after treatment in both A549 and 
MDA-MB-231 cells, however, these compounds blocked the binding of STAT3 to 
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chromatin, causing an increment of STAT3 in soluble nuclear protein fraction and 
a decline of STAT3 in chromatin-bound fraction. It was also observed that inS3-54 
and A18 suppressed the binding of STAT3 to the promoter regions of STAT3 
responsive genes in cancer cells with constitutively active STAT3 in ChIP assay 
which specifically tested two STAT3-regulated genes, cyclin D1 and twist. 
Moreover, the expression levels of STAT3 downstream targets were determined 
because STAT3 is a nuclear transcription factor that regulate the expression of 
diverse genes. InS3-54 and A18 showed inhibition of STAT3-regulated genes as 
well. Therefore, the inhibitory effects of InS3-54 and A18 on tumor cells harboring 
constitutive activation of STAT3 are demonstrated to be due to inhibition of STAT3 
downstream target expression including cyclin D1, survivin, MMP-2, -9, twist and 
VEGF. Importantly, this observation was verified in xenograft tumors as well.  
Based on the above results, we conclude tentatively that inS3-54 and its 
analogues favorably inhibit persistent STAT3 signaling by disruption of STAT3 
binding to DNA. As a result, these compounds inhibit cell proliferation, migration 
and invasion and induce apoptosis in cells with constitutively activated STAT3. 
Although the initial hit, inS3-54, may not be specific to STAT3 protein, it provides 
a good attempt for development of novel STAT3 inhibitors. A structure-activity 
analysis of inS3-54 analogues subsequently establishes a basis for further design 
and optimization of novel small molecule compounds that effectively and 
selectively block DNA-binding activity of STAT3. Of three active analogues, A18 
showed preference for STAT3 but little effect on other proteins as well as in vitro 
and in vivo effects on inhibition of aberrant STAT3 signaling. Our study supports 
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the computational modeling application in structure-based virtual screening for 
identifying STAT3 inhibitors targeting DBD and offers a promising approach to a 
new therapeutic agent for the treatment of cancer. Further studies directed at this 
strategy are currently in progress and will provide more insights into the novel 
molecular approaches to interrupt STAT3 signaling pathway for potential cancer 
therapies. Each report of a novel STAT3 inhibitor will bring an increasing optimism 
for the development of clinically useful drugs. And more in-depth analyses will 
benefit to achieving this goal, providing a promising and viable strategy for patient 
care.  
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V. Summary and Conclusion 
The experimental results of this dissertation can be summarized as follows: 
1. Using in-silico screening of a virtual compound database by docking 
onto the DNA-binding site of human STAT3, inS3-54 is identified to disrupt STAT3-
dependent signaling. 
2. InS3-54 inhibits the DNA-binding activity of STAT3 but not that of STAT1. 
3. InS3-54 directly binds to STAT3 but may also have other targets. 
4. InS3-54 may not affect activation and dimerization of STAT3. 
5. InS3-54 favorably inhibits cancer cell survival, cell migration and 
invasion in breast and lung carcinoma cells harboring constitutively active STAT3. 
6. InS3-54 prevents the binding of STAT3 to responsive DNA region via 
interaction with STAT3 protein, leading to negative regulation of STAT3 
downstream targets. 
7. InS3-54 is not applicable for further studies due to less specificity on 
STAT3 protein and poor absorption in mice; however, it can be used as an in vitro 
tool to study STAT3 function. 
8. Three active analogues of inS3-54 (A18, A26 and A69) have more 
potent or comparable activity on STAT3 signaling as compared with the initial hit, 
depending on the combination of R1 and R2 side groups in the core structure of 
inS3-54. 
9. A18, A26 and A69 are more specific to STAT3 protein than their parental 
compound, inS3-54. 
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10. A18 exerts anti-tumor effects by suppressing the DNA-binding activity of 
STAT3, causing prevention of STAT3 binding to its endogenous target sequences 
as well as down-regulation of STAT3-dependent target genes. 
11.  A18 is suitable for further studies because of acceptable solubility, 
absorption and tolerance in mice. Administration of A18 in a lung tumor xenograft 
model suppressed tumor growth with little effect on body weight or organs of heart, 
lungs, kidneys, liver and spleen.  
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VI. Future Plans 
Based on the present work, we conclude that it is possible to inhibit STAT3 
by targeting DBD for discovery of anticancer therapeutics. Future directions that 
may extend the current work contain: 
1. To further determine the direct interaction between A18 and DBD of 
STAT3 using purified protein and direct protein-ligand binding assays. The 
determination of affinity of compounds to protein will bring a better understanding 
of active determinants in these compounds in order to identify more potent and 
specific STAT3 inhibitors. 
2. To identify the potential off-target effects of A18 and to verify the 
specificity of A18 on STAT3 protein. Further studies of A18 will provide more 
evidence for development of A18 as a novel STAT3 inhibitor as well as 
demonstrate the feasibility of targeting the DBD of STAT3 in vivo. 
3. To further verify the in vivo effect of A18 on tumor growth and investigate 
whether or not A18 represses expression of STAT3 downstream targets in tumor 
tissues through more pharmacokinetic/pharmacodynamic studies. The pilot 
toxicity and efficacy studies exhibit the in vivo inhibition of A18 on tumor growth. 
PK studies will inspire optimal dosing regimens by determination of the fate of the 
compound after administration, probably improving in vivo efficacy of the 
compound.  
4. To determine the effects of A18 on metastasis and angiogenesis in 
animals. The current data indicate A18 inhibits cell migration and cell invasion as 
well as reduces the production of VEGF, suggesting its inhibitory effects on 
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metastasis and angiogenesis in vitro. More animal studies on metastasis and 
angiogenesis may be helpful in investigating in vivo effects and thereby 
determining the potential subjects who may benefit from our studies. 
5. To further optimize the structure of A18 for more potent and more 
specific STAT3 inhibitors. Although A18 emerges as a promising antineoplastic 
agent, further exploration on chemical structure will bring more evidence with 
respect to designing inhibitors targeting the DBD of STAT3.  
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